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Abstract 
Purpose 
The current project was divided into two separate, but related studies: the curcumin project and 
the apigenin project. In these projects, we aimed to assess the potential of two polyphenolic 
compounds in treating neuroinflammation and neurodegenerative disease: curcumin and apigenin. 
Curcumin project purpose (pilot study): To develop a valid UPLC-MS/MS method to quantify 
the plasma concentration of a phosphatidylcholine curcumin formulation (Meriva® curcumin), 
administered orally (via chow) to GFAP-IL6 mice for 30 days. We also endeavoured to determine 
if this formulation is able to increase bioavailability of Meriva® curcumin, in comparison to 
unformulated curcumin (naïve curcumin). We also aimed to confirm, using spectrophotometry, 
the curcumin concentration within the chow, in order to validate our experiment. 
Apigenin project purpose: To assess the viability of apigenin in rescuing motor, learning and 
memory deficits in a GFAP-IL6 mouse model of chronic neuroinflammation. 
 
Methods 
Curcumin project: For 30 days, GFAP-IL6 mice (n = 6 (2 males, 4 females) were fed one of three 
food types: Meriva® curcumin enriched chow at doses of 35, 70, and 140mg/kg.bw/day, chow 
enriched with naïve curcumin at a dose of 140mg/kg.bw/day (low bioavailability control), or 
control chow. A UPLC-MS/MS method was developed to detect curcuminoid (curcumin, 
demethoxycurcumin and bisdemethoxycurcumin) concentration in mouse plasma. To determine 
curcumin concentration in the mouse chow, 5 randomly selected pellets were homogenised, and 
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suspended in methanol. Curcumin was extracted out of solution over a 16-hour period. The 
absorbance of the resulting supernatant was measured by spectrophotometry at a wavelength of 
422nm.  
Apigenin project: GFAP-IL6 (n = 11 males, 5 females) and wild-type (WT) mice (n = 13 males, 
11 females) were fed apigenin enriched chow (400ppm) from 3 months of age till they were 18-
23 months old. The physical health, motor skills, learning and memory of the mice were assessed 
in a number of behavioural tests (walking beam, accelerod and Barnes maze). 
 
Results 
Curcumin project: The UPLC-MS/MS method developed was able to detect free curcumin in the 
plasma of the 140mg/kg.bw/day naïve curcumin group only. On the other hand, conjugate 
(curcumin sulfate and curcumin glucuronide) concentrations were higher in the 70 and 
140mg/kg.bw/day Meriva® groups than in the 140mg/kg.bw/day naïve curcumin group. 
Demethoxycurcumin could be detected in both naïve and Meriva® 140mg/kg.bw/day groups only, 
and bisdemethoxycurcumin was unable to be detected in any groups. A number of methodology 
issues, such as limited sensitivity and matrix effects were identified. Spectrophotometry results 
indicated that the mouse chow contained the expected experimental concentrations, as produced 
by the manufacturer.  
Apigenin project: The long-term administration of apigenin was able to reduce age-related weight 
loss in WT, but not GFAP-IL6 mice. Overall, apigenin was not able to improve motor function or 
learning in the mice, however apigenin was seen to improve memory for male mice in certain 
parameters. Sex effects were observed in a number of test parameters. 
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Conclusion 
Curcumin project: The UPLC-MS/MS method developed was able to detect and quantify 
curcumin and demethoxycurcumin, however, could not detect bisdemethoxycurcumin. Future 
experiments will need to address issues such as matrix effects and sensitivity to improve the 
method. Although free curcumin was detected only in the 140mg/kg.bw/day naïve curcumin 
group, a higher conjugate concentration in the 70 and 140mg/kg.bw/day Meriva® groups suggests 
that the Meriva® formulation was able to improve bioavailability initially, but was rapidly 
metabolised. 
Apigenin project: Based on its ability to rescue behavioural deficits in GFAP-IL6 mice, apigenin 
may not be an appropriate treatment for neuroinflammation and neurodegenerative disease. 
However, its long term administration may be useful in reducing age-related weight loss in non-
demented elderly population. Further testing with a larger sample size is required to confirm the 
findings in this study, particularly in relation to any sex effects seen. 
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1. Introduction 
By 2040, the World Health Organization (WHO) has predicted that neurodegenerative disease will 
surpass cancer as the second leading cause of death globally, behind cardiovascular disease (1). 
The global cost of dementia alone is expected to reach USD $1 trillion dollars annually by 2018 
(2). With the substantial financial and societal cost of neurodegenerative disease becoming 
increasingly rampant, the race to find effective treatments, and ideally a cure, is ever pressing. 
Neurodegeneration is a complex process, characterised by the degradation and eventual death of 
neurons in the central nervous system (CNS) (3). As a result of the neurodegenerative process, a 
range of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) 
and Motor neuron disease can occur. Although the exact mechanisms behind neurodegenerative 
diseases are not completely understood, the growing awareness of the contribution of nervous 
tissue inflammation (termed “neuroinflammation”) to the pathogenesis and progression of these 
diseases (4) has increased rapidly in recent years, and has undoubtedly led to the plethora of 
interest in viewing neuroinflammation as a therapeutic target and thus, the development and 
application of a range of anti-inflammatory drugs.  
Traditional treatments such as steroidal drugs and non-steroidal anti-inflammatory drugs 
(NSAIDs), while effective in providing symptomatic relief, can result in a number of side effects 
when used long-term (5). Furthermore, these drugs are not effective in attenuating 
neuroinflammation and therefore do not provide a cure of neurodegenerative diseases (6), and are, 
therefore, limited in their ability to alleviate the societal burden of these diseases. Consequently, 
with the prevalence of neurodegenerative diseases expected to rise sharply over the next century, 
there is a great need to identify alternative therapies that are able to be used with fewer side effects 
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to treat and prevent neurodegenerative diseases. One alternative being considered is the use of 
cytokine-suppressive anti-inflammatory drugs (CSAIDs), which unlike traditional treatments, 
have broader anti-inflammatory effects with diminished side effects (7, 8). 
In the present study, we investigated the potential of two polyphenolic CSAIDs, curcumin and 
apigenin (Fig 1), in their potential as treatments for neurodegenerative disease, in a GFAP-IL6 
transgenic mouse model of neuroinflammation.  Polyphenols, derived from a number of plant 
sources, are known to exhibit a wide range of anti-inflammatory effects with little to no toxicity, 
even at high doses (9, 10). Thus, curcumin and apigenin may represent a viable alternative to 
current treatments of neurodegenerative diseases. We, therefore, aim to test the above compounds 
to ascertain their potential in the treatment of neuroinflammation.  
 
 
Fig 1. Chemical structure of curcumin and apigenin. Source: Angulo et al 2017, Journal of Hematology & 
Oncology, 10, 10 (11) 
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1.2 Neuroinflammation and neurodegenerative disease 
As it is understood today, the term “neuroinflammation” refers to a CNS-specific inflammatory 
response mediated by glial cells, predominantly microglia and astrocytes (12). This response is 
dissimilar to that of the periphery, and can result in the occurrence of neurodegenerative events 
such as tau phosphorylation and the formation of amyloid plaques (13). 
For many years, the CNS was considered an “immunologically privileged” site, distinct from the 
peripheral immune system (13, 14), due in part to the blood-brain barrier (BBB) which selectively 
restricts the ingress of a variety of substances from the blood-stream to the brain (15). However, 
contrary to this initial belief, a multitude of studies have demonstrated that significant and 
continuous cross-talk between the peripheral immune system and the CNS (16, 17), resulting in a 
specialised immune system that is able to elicit a dynamic inflammatory and immune response 
within the CNS (18, 19).  
The neuroinflammatory response is, in fact, a crucial brain response that aims to repair, remove 
and regenerate damaged materials within the CNS (20). The two key players in this response are 
the resident microglia and astroglia which become activated in response to an inflammatory 
stimulus, altering their morphology, and releasing various pro-inflammatory cytokines such as 
tumour necrosis factor (TNF) α, interferon-γ (IFN-γ), and interleukin-6 (IL-6) (21), as well as 
numerous chemokines (22). Along with the release of these pro-inflammatory factors, the glial 
response also results in the up-regulation of a number of pro-oxidant molecules, including nitric 
oxide (NO) and superoxide (O2), which serve as a further defence mechanism in protecting against 
injurious organisms (23). Neuroinflammation is also mediated by several other immune and 
inflammatory cells including T-cells, mast cells, neutrophils, neurons, and the inflammatory 
mediators these cells release (24, 25).   
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The inflammatory response is generally short lived (acute) and tends to subside once the 
inflammatory stimulus has been removed, and any damage repaired (26). At this stage, any 
nitrosative or oxidative stress that has occurred is unlikely to result in permanent damage to 
neurons, and thus, this initial neuroinflammation proves beneficial in addressing injurious stimuli 
and restoring homeostasis within the system (20, 27). However, a prolonged (chronic) 
inflammatory response signifies that an inflammatory stimulus continues to subsist and, therefore, 
suggests a deterioration in anti-inflammatory mechanisms (26). This chronic neuroinflammation 
results in a self-propelling cycle where sustained activation of glial cells leads to additional and 
continued release of inflammatory factors, which in turn activates further glial cells – perpetuating 
the cycle once again (27). If the inflammatory stimulus is not removed, and neuroinflammation 
continues unchecked, this will eventually lead to neuronal death (12). A prolonged 
neuroinflammatory response is, therefore, believed to be a contributing factor in neurodegenerative 
diseases (Fig 2). 
A myriad of neurodegenerative diseases including multiple sclerosis, PD and AD have been linked 
with the occurrence of chronic neuroinflammation (28). In fact, despite a considerable difference 
in the pathogenesis between different neurodegenerative diseases, chronic neuroinflammation is 
an underlying mechanism that is common to all (29, 30). However, the exact extent of the 
contribution of neuroinflammation to neurodegenerative diseases, and its mechanisms, aren’t 
entirely understood. 
 5 
 
 
Fig 2. The neuroinflammatory response in neurodegenerative disease. Source: Morales et al 2014, Frontiers in 
cellular neuroscience, 8, 1-9 (12) 
 
Given the knowledge that neuroinflammation is a self-perpetuating cycle that is a major 
contributor in the pathogenesis of a range of neurodegenerative diseases, it is unsurprising that this 
symptom has been increasingly explored as a therapeutic target, particularly with regards to 
investigating means to break this cycle, with the ultimate goal of reducing the onset of these 
diseases and slowing their progression.    
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1.2.1 Chemical mechanisms of inflammation response and role of phenolics (31) 
The reactive free radical nitric oxide is produced from L-arginine by the enzyme nitric oxide 
synthase (NOS) (equation 1), in a process activated by IFN-γ and TNF.  NO• causes radical-
induced DNA damage and iron-sulfur centre degradation, leading to cell death of pathogens.   
L-Arg + O2 + NADPH   →   NO• + citrulline         (Equation 1) 
Superoxide, another reactive free radical, is generated (equation 2) in phagocytes by reduction of 
molecular oxygen by the enzyme NADPH oxidase. 
2 O2 + NADPH oxidase   →   2 O2-•   + NADP+   + H+   (Equation 2) 
In turn, superoxide is converted into hydrogen peroxide by its reaction with superoxide dismutase 
(3). 
2 O2
-•   + 2 H+   →   H2O2       (Equation 3) 
Superoxide and hydrogen peroxide give rise to a number of other reactive oxygen species such as 
alkyl radicals (R•), alkylperoxyl radicals (ROO•), alkoxyl radicals (RO•) and hydroxyl radical 
(HO•).  These species kill pathogens by undergoing radical addition and hydrogen abstraction 
chain processes which oxidise cellular proteins and lipids and damage DNA. 
Phenolic compounds act as chemical agents which terminate these free radical chain processes by 
hydrogen atom donation.  For instance, an alkyl radical (R•) will abstract a hydrogen atom from a 
phenol, forming a benign alkane (RH) and a stabilised, unreactive phenoxyl radical, which 
subsequently degrades to non-radical products (4). 
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     (Equation 4) 
 
1.3 Current treatment of neuroinflammation 
Regardless of the origins of chronic neurodegenerative diseases, inflammation is generally the 
primary therapeutic target, the focus of which has increased substantially in recent years (32). At 
present, no therapeutic agents are capable of repairing or regenerating neurons, delaying the onset 
of neurodegenerative disease, or preventing further degeneration from occurring. Rather, currently 
available treatments aim to alleviate the symptoms of the disease and to improve the quality of life 
for patients (4, 26, 33). 
While it would not be possible to explore all the available treatments of neuroinflammation, the 
key focus of this section will be on the two main classes of drugs that are used to target the 
neuroinflammatory process; NSAIDs and steroidal drugs. 
 
1.3.1 Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs encompass a vast array of molecules that are believed to restrict the activity of 
cyclooxygenase (COX) 1 and 2, and thus the production of prostaglandins – a group of lipids that 
are involved in a number of key functions driving the inflammatory process (32). NSAIDs 
potentially have other mechanisms of action including the activation of the peroxisome 
proliferator-activated receptor c (34). 
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The idea that NSAIDs would constitute an effective treatment of neuroinflammation originates 
from a number of epidemiological studies that have demonstrated that long-term use of NSAIDs 
results in reduced cognitive decline, delays the onset of dementia, and lowers instances of AD in 
later life (35, 36).  
Both in pre-clinical and epidemiological studies, NSAIDs have proved beneficial in treating 
neuroinflammation and neurodegenerative symptoms. For example, Jain et al 2002 (37) found that 
the chronic administration (over a 7-day period) of 192 mg/kg, per os (p.o) of rofecoxib was 
effective in diminishing lipopolysaccharide (LPS)-induced cognitive deficits in mice. In an 
epidemiological study investigating nearly 50,000 patients with AD, and nearly 200,000 control 
subjects found that the use of NSAIDs reduced the instances of AD if used long-term i.e. more 
than 5 years (38).  
However, this success has not necessarily been translated to clinical trials. For instance, in a human 
clinical trial (39), 25mg of rofecoxib, or a placebo, was administered over a 1-year period to 692 
patients (481 patients completed the study) over 50 years old with mild-to-moderate AD. In this 
study, no significant difference was observed between control and treatment groups on a number 
of efficacy measures e.g. the cognitive subscale of the AD Assessment Scale (ADAS-cog). 
Similarly, in a randomized, double blind study investigating the effects of naproxen in reducing 
AD progression (40), a sub-therapeutic dose of the drug (440mg/day) was administered over a 12-
month period to 118 patients, while 111 patients were placed on a placebo. The results from this 
study indicated that there was no difference in deterioration between drug and placebo groups. In 
another long-term study (41), it was found that the relative risk for AD declined to 0.2 (95% CI 
0.05-0.83) for long-term users of NSAIDs (>24 months use). However, for those taking NSAIDs 
for 23 months or less, a non-significant decline to 0.83 (95% CI 0.62-1.11) was observed.  
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The inconsistency of NSAIDs observed across the literature raise important questions regarding 
their efficacy in targeting neuroinflammation. In particular, the question remains whether the use 
of NSAIDs is viable to treat neuroinflammatory diseases, such as AD, in the first place. The 
application of NSAIDs may be useful only as a preventative means, as once disease progression 
occurs, administration of NSAIDs may do more harm than good as they inhibit all activity of 
microglia, including their reparative properties (42). NSAIDs may also have limited efficacy in 
the treatment of neuroinflammation, given that NSAIDs may not suppress pro-inflammatory 
cytokines, e.g. IL-6 or TNF-α, and in some cases, can even increase cytokine levels (43, 44). Other 
experimental factors, such as the use of appropriate doses, the type of NSAID used, and the dosing 
schedule should also be considered in the interpretation of NSAID efficacy in the literature (45). 
In addition, the long-term use of NSAIDs is associated with a number of adverse side effects, 
including gastrointestinal issues such as bleeding or ulcers (46, 47), increased risk of 
cardiovascular complications (48) or renal impairment (49). These side effects severely limit the 
scope of NSAID use in a clinical setting. 
 
1.3.2 Steroidal drugs 
Steroidal drug studies investigating neuroinflammation and neurodegeneration are less prevalent 
than those exploring NSAIDs; indicative of the level of usage of NSAIDs in comparison to steroids 
in the general population (50). Steroidal drugs are known to inhibit COX-2 activity, and in a 
general sense, alter gene transcription, resulting in a diminished level of synthesis for particular 
proteins. For example, glucocorticoids in particular can inhibit the activity of the transcription 
factor “AP-1” which results in diminished secretion of numerous pro-inflammatory cytokines (50, 
51). 
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Glucocorticoids in particular, are one of the most effective and powerful ant-inflammatory drugs, 
however their appropriateness in treating neurodegenerative disease has been heavily scrutinized 
due to toxicity concerns and adverse effects associated with their use such as osteoporosis, adrenal 
suppression and behavioural disorders (52). Their effectiveness in treating neurodegenerative 
symptoms is also questionable. In one study, a low dose clinical study administered 20mg of the 
glucocorticoid, prednisone, to patients with probable AD for a period of 4 weeks. It was found that 
there was no significant difference in cognitive decline between the prednisone treated and control 
groups (52). Another study (53) found that the administration of 5-40mg/day of prednisone for 12 
months resulted in diminished hippocampal-independent explicit memory, which would likely 
counterbalance any anti-inflammatory effects in the treatment of neurodegenerative diseases.  
On the other hand, the use of steroidal drugs has been used to treat relapses in patients with MS 
(54-56). The mechanisms behind this efficacy, however, are unclear.  
 
1.4 The need for an alternative 
It is evident that the effective utilization of steroidal and NSAIDs in the treatment of 
neuroinflammation and neurodegenerative disease is highly context dependent and exceptionally 
challenging. Many studies that investigate these treatments are plagued with a number of issues 
that are likely to affect their results such as the use of small sample sizes, the investigation of short-
term effects of the administration of the drug (as opposed to the investigation of long-term 
impacts), or using an inappropriate dose necessary for clinical efficacy. The usefulness of current 
treatments in treating neuroinflammation is not particularly clear at this point, and with deleterious 
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side effects associated with their use, it is evident that other options need to be explored to achieve 
effective treatment of neurodegenerative disease. 
With the expectation that global incidences of neurodegenerative diseases will rise sharply over 
the next century, and the questionable effectiveness of current treatments, it is clear that there is a 
crucial need to identify alternative disease-modifying therapeutic options that can be used long-
term with minimal adverse side effects. One such option that has been suggested to target 
neuroinflammation is CSAIDs. 
The emergent understanding of the crucial role that cytokine production plays in the inflammatory 
process has resulted in an augmented interest in investigating ways to dysregulate this cycle. 
CSAIDs work by disrupting inflammatory signaling cascades, inhibiting the function of pro-
inflammatory factors such as the p38 mitogen-activated protein kinase (MAP kinase), which 
reduces the influence of cytokines on the system, as well as limiting their overall production (57, 
58). Furthermore, most CSAIDs have little to no side effects when used long-term (8, 9). Naturally 
occurring phytochemicals termed polyphenols, are found in a variety of dietary plant materials, 
and are considered in this study as promising CSAID candidates, given they have well 
demonstrated anti-inflammatory effects (59). CSAIDs may, therefore, represent a promising 
therapeutic agent in treating neurodegenerative diseases. In this study, we investigate two 
polyphenols; curcumin and apigenin, and their potential treatment of neuroinflammation and 
neurodegeneration in a GFAP-IL6 transgenic mouse model.  
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1.4.1 Curcumin 
Turmeric, a yellow aromatic spice derived from the rhizome of the plant Curcuma longa L, has 
long been utilised to flavour Indian and South-east Asian cuisine (60), and to treat a range of 
ailments including respiratory disorders, bites and burns (61). 
Turmeric contains more than ten polyphenolic bioactive compounds known as curcuminoids, of 
which the most abundant and active are curcumin, demethoxycurcumin and 
bisdemethoxycurcumin (62) (Fig. 3). Commercially available turmeric comprises of all 3 of the 
above curcuminoids in the ranges of 70-75%, 15-20% and 5-10% respectively (63) alongside other 
components including essential oils, proteins, carbohydrates, lipids and minerals (64). 
 
 
 
Fig 3. Molecular representation of the curcuminoids; curcumin, demethoxycurcumin and 
bisdemethoxycurcumin. Curcumin contains two methoxy groups, as indicated by the red circles, whereas 
demethoxycurcumin contains only one methoxy group, and bisdemethoxycurcumin, none. Source: Volak et al 2008, 
Drug Metabolism and Disposition, 36: 1594-605 (65) 
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Of particular interest, curcumin and its properties have been widely investigated in the literature. 
Curcumin has demonstrated anti-inflammatory, anti-cancer, anti-fungal, anti-mutagenic, 
antioxidant, neuroprotective and anti-amyloidal properties (66), and is shown to provide a number 
of benefits in the treatment and prevention of a wide range of diseases including diabetes, Crohn’s 
disease, cardiovascular ailments and AD (67). Curcumin is thought to work by modulating 
molecular targets, enzymes, cell receptors, cytokines and chemokines by modifying signalling 
pathways and target gene expression (68-70). However, whilst showing considerable efficacy in 
cell culture studies, much of this success has not been translated in pre-clinical and clinical studies 
(68).  
The reason for this incongruity lies in the fact that curcumin has poor bioavailability. It experiences 
degradation at physiological pH (71), has limited gut absorption, and is rapidly metabolised and 
eliminated after oral consumption (72). However, if curcumin does reach the plasma, its stability 
increases substantially, and it is even able to permeate relatively inaccessible tissues such as the 
brain (73).  
After oral administration, curcumin is metabolised by both Phase I and Phase II metabolites. Phase 
I metabolism involves bioreduction to form a number of reduced metabolites including 
tetrahydrocurcumin, dihydrocurcumin, and hexahydrocurcumin. These metabolites may exist in 
either free forms, or conjugates (68). In Phase II metabolism, metabolic O-conjugation occurs, 
resulting in the formation of curcumin glucuronide and curcumin sulfate (74). The two other major 
curcuminoids (demethoxycurcumin and bisdemethoxycurcumin) are also believed to undergo 
similar metabolism to that which is seen in curcumin (75). A number of studies have shown that 
curcuminoid metabolites form the majority of curcumin content in both human and animal plasma 
(60, 76), although their bioactivity requires further research. 
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With the potential of curcumin to aid in the pathology of numerous diseases, research has begun 
to focus on developing techniques to improve absorption in the gut and improve the efficacy of 
the drug. For example, curcumin can be formulated with other compounds such as piperine or 
liposomes (77, 78), or can be produced as nanoformulations (79) – all of which have been shown 
to improve absorption of curcumin in vivo (80-82). 
Another technique that is being investigated as a means of enhancing the absorption of curcumin, 
is the use of a patented curcumin-phytosome complex: Meriva® curcumin. Meriva® curcumin is 
a phytosomal formulation of curcumin with soy lecithin (1:2 weight ratio) and two parts 
microcrystalline cellulose. A phytosome (Fig 4), while being a similar drug delivery system to a 
liposome, is somewhat different. In liposomal delivery systems, the drug is dissolved in the 
medium contained in the cavity within the phospholipid bilayer. However, with a phytosomal drug 
delivery system, the drug becomes a fundamental part of the membrane, with a higher chance of 
molecular interaction between the lipid membrane and a hydrophilic substance, improving the 
absorption of the drug, relative to liposomal delivery systems. 
Studies investigating Meriva® curcumin have found that this formulation has demonstrated 
efficacy in osteoarthritis pain management (83), improving diabetic microangiopathy (84), and 
aiding in pain management, while also reducing the number of relapses of patients with uveitis 
(85), an infection of the middle eye. In addition, a previous study (63) found that in human subjects, 
the average absorption of Meriva® curcumin was 18-fold higher than unformulated curcumin, and 
29-fold higher for total curcuminoid content. However, the study was unable to detect 
unconjugated curcumin in the plasma, and thus had to treat samples with the enzyme β-
Glucuronidase from the snail Helix pomatia to recover parent compounds. 
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Fig 4. A comparison of the phytosome technology, used as a drug delivery system in a number of drugs such as 
Meriva® curcumin, and a liposomal drug delivery system. Source: Indena 2017: http://www.phytosome.info/ 
Accessed 22nd September, 2017 (86). 
 
To date, the specific concentrations of Meriva® curcumin able to reach the plasma in both animal 
models, and human clinical trials, remains unknown. The quantification of other formulated and 
non-formulated curcumin complexes, however, have been studied in a number of pharmacokinetic 
and metabolism studies where administration of the drug is often applied short-term and 
curcuminoids are quantified within hours of initial administration. In the majority of these studies, 
free curcuminoid concentration in plasma is often at low or negligible levels. For example, in one 
study (87), rats were administered a dose of 50mg/kg of unformulated curcumin. No free curcumin 
was able to be detected in the plasma up to 120 minutes after administration (87). However, with 
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the higher dose of 500mg/kg, administered orally, the maximum concentration (Cmax) was found 
to be 0.06±0.01ug/mL in rat plasma (88). 
Long-term application of curcumin, or curcumin complexes are limited in the literature, both in 
animal and human studies. Regardless, these studies often have limited success, with low plasma 
concentrations recorded. In one study, 2-4g of Curcumin C3 Complex® was administered daily 
for 24 weeks to human subjects. Even after such a time period, the mean curcumin concentration 
in plasma was found to be low at 7.32ng/mL (89). 
On the other hand, exemplifying the ultra-effective metabolism of curcumin, a number of studies 
have found that metabolites, such as conjugates, form the majority of curcuminoid matter in the 
plasma. For instance, Li et al 2011 (90) investigated the metabolism and pharmacokinetics in 
tumour-bearing ICR mice, and found that curcumin conjugates (sulfates and glucuronides) were 
the main forms of curcumin-related product in the plasma. Similarly, Chen et al 2012 (91) 
administered 4g of curcumin C3 complex® orally to two human subjects, where they unable to 
detect any free curcumin in the plasma up to 24 hours’ post-administration. However, they were 
able to detect a maximum concentration of 167.5ng/mL of the conjugate, curcumin-O-glucuronide. 
 The potential of formulated curcumin in improving absorption was made quite clear in a previous 
study by Suresh and Srinivasan 2010 (92), which found that piperine-formulated curcumin was 
able to be detected in rat plasma eight days after oral administration as opposed to unformulated 
curcumin that was unable to be detected up to 24 hours. Other studies have used analytical 
chemistry methods such as HPLC to compare responses between various formulations or in 
different brain regions by comparing the area-under-the-curve (AUC) without quantifying exact 
concentrations (82). 
Detection of curcuminoids in the plasma appears to be dependent on the dosage used in the study, 
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the method of administration of the drug (e.g. oral gavage vs i.p. injection), the type of formulation 
tested, as well as the analytical methods used for detection. For example, ultra-performance liquid 
chromatography – tandem mass spectrometry (UPLC-MS/MS) has the potential to be a far more 
sensitive detection method than HPLC with ultraviolet (UV) detection (93, 94). Therefore, 
comparison of results is difficult. Additionally, UPLC-MS/MS method development is plagued 
with a number of issues affecting accuracy and precision, particularly when dealing with complex 
biological matrices such as plasma. For instance, matrix effects, caused by interfering compounds 
within the sample other than the analyte of interest, can result in an altered signal response, which 
therefore impacts on the precision and accuracy of the experiment (95). Furthermore, sensitivity 
issues may arise when dealing with minimal quantities of analytes within a sample, which are not 
easily resolved (96, 97). However, it appears that if the above factors are considered, and accounted 
for, there is the potential for curcumin to be detected and quantified accurately.  
 
1.4.2 Apigenin 
Apigenin (Fig 5) is one of the most common dietary flavonoids, ubiquitous in a range of fruits, 
vegetables and other plant materials including parsley, chamomile and celery (98, 99). The 
medicinal properties of apigenin have been recognized and applied for centuries. For example, 
chamomile tea, rich in apigenin, has been utilized in the treatment of gastrointestinal issues such 
as indigestion (100), and as a relaxant (101). 
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Fig 5. Apigenin molecule. Source: Sigma-Aldrich 2017: 
http://www.sigmaaldrich.com/catalog/product/aldrich/460745?lang=en&region=AU, Accessed 22nd September, 
2017 (102). 
 
Evidence from the literature suggests that apigenin possesses a number of key therapeutic 
properties including anti-oxidant (103), anti-carcinogenic (104) and anti-inflammatory effects 
(105). However, much of the literature focus to date has highlighted the anti-carcinogenic 
properties of the molecule, and this has been predominantly explored in cell culture studies. 
The efficacy of apigenin as an anti-inflammatory agent has been demonstrated in a number of 
studies. For example, the level of the pro-inflammatory cytokine IL-6 was reduced in 
lipopolysaccharide (LPS) -activated mouse macrophages (106). Other studies have demonstrated 
that through the inhibition of inducible nitric oxide synthase (iNOS) and COX-2, the expression 
of inflammatory factors including NO and prostaglandin were reduced in mouse macrophage and 
microglial cells (107, 108). Apigenin was also shown to possess other anti-inflammatory properties 
such as the deactivation of nuclear factor kappa-beta (NF-κB) and TNF (109, 110) – both key 
players in the neuroinflammatory process. 
However, any progression of these anti-inflammatory effects from cell culture studies into animal 
models has been extremely limited, and thus, the effect of apigenin in vivo is not well understood. 
Nevertheless, a number of animal studies have been conducted in recent years. One example is a 
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study (111) that found that 7-month old APP/PS1 mice fed 40mg/kg.bw/day demonstrated 
improved learning and memory in a Morris water maze (MWM) test. Another study found a dose-
dependent improvement in rotarod performance of male mice injected with 1-methyl-4-phenyl-1, 
2, 3, 6-tetrahydropyridine (MPTP) to simulate PD-like symptoms (112). Apigenin has also been 
shown to improve memory and learning, as well as inhibiting the release of a number of 
inflammatory markers in numerous studies (113, 114). To the knowledge of this author, no study 
has been conducted to investigate the efficacy of apigenin in human trials with a 
neuroinflammation/neurodegeneration focus. In the minimal animal studies conducted, apigenin 
has shown improvements in motor function and cognition, although the mechanisms behind this 
improvement are not entirely understood, meaning further studies are necessary. 
 
1.5 The GFAP-IL6 mouse model 
Expression of the pro-inflammatory cytokine, IL-6 has been implicated in the progression of a 
number of neurodegenerative diseases including AD and stroke (115, 116). During the 
inflammatory process, IL-6 is believed to play a crucial role in communication between the CNS 
and the periphery (117). 
The development of the GFAP-IL6 model aimed to shed light on the neurological effect of IL-6, 
as well as the mechanisms linking chronic neuroinflammation, cognition and neurodegeneration 
(118, 119). In this transgenic model, IL-6 from astrocytes is produced consistently in low levels, 
and regulated by the glial fibrillary acid protein (GFAP) promoter (118, 120). Given the continual 
production of IL-6, a permanent state of escalating neuroinflammation develops in the GFAP-IL6 
animals, resulting in age related decline in motor function and cognition (118). 
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In wild-type (WT) mice, IL-6 is undetectable in the brain, however, IL-6 is found in elevated levels 
in the cerebellum, hippocampus, hypothalamus, the striatum, the neocortex and the pons of GFAP-
IL6 mice, inducing age-dependent structural changes within 3-6 months (121). Similarly, in human 
patients with AD, IL-6 is detectable in the brain. However, in elderly non-demented humans, IL-
6 is non- detectable (122). Additionally, as with neurodegenerative decline in humans, GFAP-IL6 
mice demonstrate a number of recognisable traits such as spontaneous seizures, hunched posture, 
and cognitive decline (123, 124). These links between animal models and the pathogenesis of 
neurodegenerative diseases in humans indicate that the use of the IL-6 cytokine is an appropriate 
cytokine to investigate in an animal model of chronic neuroinflammation. As such, this mouse 
model has been used previously by our group to test the efficacy of the nootropic drug, Tenilsetam, 
in reducing neuroinflammation (43). 
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2. Hypotheses and aims 
2.1 Hypotheses  
Chronic neuroinflammation and its role in neurodegeneration is a complex process that is not 
understood in its entirety. However, it is clear that current treatments to address neuroinflammation 
in neurodegenerative diseases present a number of issues in terms of their clinical efficacy and 
deleterious side effects associated with their long-term use. We, therefore, propose that the 
application of the polyphenolic CSAIDs, Meriva® curcumin and apigenin, may be suitable options 
in the treatment of neuroinflammation, given the presence of a number of disease modifying 
properties and the brain permeability of the molecules. In order for the drugs to be effective in 
treating neurodegenerative symptoms, it is crucial that the drug is able to reach the blood in 
therapeutic levels, and that it is capable of altering behavioural phenotypes. 
As such, we hypothesise that: 
1. Curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) will be 
present at detectable levels in the plasma of GFAP-IL6 mice which have been fed 
Meriva® curcumin for 1 month. 
2. Curcuminoid levels will be able to be detected in the mouse plasma with the development 
of a valid UPLC-MS/MS method. 
3. Meriva® curcumin will be more bioavailable than the low bioavailability unformulated 
curcumin. 
4. Long-term feeding of apigenin will attenuate cognitive decline and deterioration of motor 
skills in aged GFAP-IL6 mice.   
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2.2 Aims  
 
2.2.1. Meriva® curcumin project 
Aim 1.  To determine the concentration of total curcuminoids in mouse chow pellets used for oral 
administration of Meriva® curcumin to ensure the experimentally determined concentration of 
curcuminoids in the mouse chow pellets will match the expected concentration as specified by the 
manufacturer of the chow. 
Aim 2. To develop a valid UPLC-MS/MS method to determine the concentration of curcumin, 
demethoxycurcumin and bisdemethoxycurcumin (including sulphated and glucuronidated forms) 
in mouse plasma from mice fed with Meriva® or naive curcumin for 1 month (pilot study). 
 
2.2.2. Apigenin project 
Aim 3.  To determine the efficacy of apigenin after long term feeding (from 3 months of age) in 
being able to improve motor function, learning, spatial awareness and memory in GFAP-IL6 
transgenic mice. 
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3. Methods 
3.1 Ethics 
The experimental procedures carried out in this project were approved by the Animal Research 
Ethics Committee of Western Sydney University (A11393).  
 
3.2 Methods for Aim 1 
Determine the concentration of curcumin in mouse chow pellets used for oral administration of 
Meriva® curcumin to ensure the experimentally determined concentration of curcumin in the 
mouse chow pellets will match the expected concentration as specified by the manufacturer of the 
chow. 
 
3.2.1 Mouse chow formulation 
Meriva® curcumin (developed by Indena, SpA), containing 75-percent curcumin, 15-percent 
demethoxycurcumin and 10-percent bisdemethoxycurcumin (of 100% curcuminoid content) was 
prepared by Sigmar Italia SpA, Almè, Italy. The prepared formulation was sent to “Specialty 
Feeds”, a company specialising in the development of laboratory animal feeds, where the prepared 
Meriva® formulation, and naive curcumin, was added to standard mouse chow pellets. The pellets, 
containing grain products, plant materials, vegetable oils, fish, meat, minerals, and other “natural” 
materials, were formulated to meet the dietary requirements of the experimental animals 
(consisting 20.00% protein, 4.80% crude fibre, 4.80% total fat, and 14.0MJ/Kg digestible energy).  
The curcumin concentrations added to the standard mouse chow pellets are set out in Table 1. The 
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corresponding experimental doses were calculated based on the approximation that the mice would 
eat around 5.00g of chow per day, with an average mouse weight of 25.0g 
Table 1. Curcumin* concentration and corresponding experimental doses for mouse chow pellets 
Formulation Type Mass of 
formulation added 
(g/kg)** 
Mass of 
curcumin 
contained in 
pellet (g/kg)*** 
Corresponding 
experimental dose 
(mg/kg.bw/day) 
Control 0 0 0 
Meriva® 1.09 0.22 35 
Meriva® 2.18 0.44 70 
Meriva® 4.37 0.87 140 
Naïve (unformulated) 0.87 0.87 140 
 
*Curcumin mass described refers to curcumin only, and does not include demethoxycurcumin or 
bisdemethoxycurcumin mass 
**Including the weight of the phytosome 
*** Excluding the weight of the phytosome. Naïve curcumin is not contained within a phytosome 
 
The mouse chow pellets were stored at room temperature in vacuum packed bags in the animal 
housing facility at the School of Medicine, Western Sydney University 
 
3.2.2 Determination of curcumin concentration in the mouse chow 
A random selection of mouse chow pellets (5 pellets, of similar size) from each curcumin 
formulation were homogenised using a mortar and pestle to produce a fine powder. The 
concentration of curcumin expected in each sample are listed in Table 1.  
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For each formulation, a total of three separate samples were prepared. A mass of 0.500g of 
homogenized pellet of each concentration (including control feed) was suspended in 30mL of 
methanol in a 50mL falcon tube. The samples were then sonicated for 30 minutes at 40°C, and 
placed on a shaker at 99rpm for 16 hours. After shaking, all samples were centrifuged at 3000g for 
five minutes, after which the supernatant was collected for analysis. 
Standard solutions for calibration curves were prepared from a 1mM stock solution and diluted 
with methanol to make concentrations of 50µM, 20µM, 10µM and 0µM. 
The absorbance of all solutions was measured in triplicate using a Shimadzu UV-2550 UV/Vis 
spectrophotometer at a wavelength of 422nm. 
The concentration of the methanol samples was calculated using the Beer-Lambert law: 
 
A = ϵ x c x l 
 
Where: 
A = absorbance of solution (measured by spectrophotometer) 
ϵ = molar attenuation coefficient for curcumin (a value 55,000 for curcumin in a methanol 
solution was used (125)) 
c = concentration of solution (M) 
l = path length i.e. the width of the cuvette over which the light travels, in this case 1cm 
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3.3 Methods for Aim 2 
To develop a valid UPLC-MS/MS method to determine the concentration of curcumin, 
demethoxycurcumin and bisdemethoxycurcumin (including sulphated and glucuronidated forms) 
in mouse plasma from mice fed with Meriva® or naive curcumin for 1 month (pilot study). 
 
3.3.1 Mouse feeding and plasma collection 
For each dosage of curcumin tested, the plasma from one mouse (4 months of age) was used, with 
treatment groups set out as in Table 2. We aimed to ascertain whether curcumininoids (and their 
conjugates) could be detected in the plasma, and if so, to measure their concentrations so that 
future studies may be adjusted to accommodate this knowledge. Mice had free access to chow and 
water for a period of one month (30 days), after which they were anaesthetised using isofluorane 
and their blood collected in centrifuge tubes after decapitation. Oral gavage did not seem 
appropriate in this in this instance, as we aimed to reduce the amount of stress placed on the 
animals. The blood samples were centrifuged at 6000g for five minutes to obtain the plasma, which 
was stored at -80°C until the time of analysis. The volume of plasma obtained from each mouse 
varied from approximately 50µL to 300µL.  
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Dosage (mg/kg.bw/day), 
formulation 
Genotype fed Mass curcumin/kg 
(g)* 
 # Mice 
tested 
Sex of 
mouse 
0 WT 0 1 F 
0 GFAP-IL6 0 1 F 
35, Meriva® GFAP-IL6 1.09 1 M 
70, Meriva® GFAP-IL6 2.18 1 F 
140, Meriva® GFAP-IL6 4.37 1 M 
140, naïve (low 
bioavailability control) 
GFAP-IL6 0.87 1 F 
*Including weight of phytosome (naïve curcumin is not contained within a phytosome) 
 
3.3.2 UPLC-MS/MS experimental procedure 
3.3.2.1 Chemicals and reagents 
USP reference standards for demethoxycurcumin and bisdemethoxycurcumin (100% purity) were 
used (USP Rockville, MD) and provided by Indena, SpA (Milan, Italy). A curcumin reference 
standard was also provided by Indena, SpA (Milan, Italy; CAS no.458-37-7). LC-MS grade 
Acetonitrile (>99.9% purity, Burdick and Jackson), and ethyl acetate (>99.5% purity, Merck) were 
obtained commercially. Β-Glucuronidase from Helix pomatia was acquired from Sigma-Aldrich 
(St. Louis, MO; CAS no. 9001-45-0). Other chemicals and reagents used in the samples included 
LC-MS grade formic acid (90% purity), purchased from Chem-Supply (SA, Australia), and 
ascorbic acid (>99.5% purity) obtained from Sigma-Aldrich (St. Louis, MO; CAS no. 50-81-7). 
Ultrapure water used in all experiments was acquired from a Milli-Q Gradient system (Merck 
Millipore), with resistivity of 18.2 MΩ.cm at 25°C”.  
Table 2. Group designation for UPLC-MS/MS analysis of mouse plasma 
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3.3.2.2 Standard preparation 
6.0 mg of each curcuminoid reference standard (curcumin, demethoxycurcumin and 
bisdemethoxycurcumin) was dissolved in 1:1 ultrapure water: acetonitrile and made up to 100.0mL 
in a standard volumetric flask, giving a mixed curcuminoid stock solution of 60µg/mL of each 
compound. This stock solution was stored at -20°C until the time of experimentation. Working 
solutions were prepared by diluting the stock solution 1: 80 yielding a solution with a concentration 
of 750 ng/ml for each of the three curcuminoids. 
Spectrophotometric analysis using a standard curve ranging up to a maximum absorbance value 
of 3.1 and UV/VIS absorption at 422 nm showed that working solution to have a concentration of 
674.1 ng/ml (from an expected 750ng/mL concentration). When the standard curve was 
recalculated to only include absorbance values up to 1, then the concentration was calculated to be 
739.0 ng/ml. Combining these different results (750 ng/ml by weight and 674.1 or 739 ng/ml by 
spectrophotometry), the concentration of the working solution was agreed to be 700 ng/ml, and 
this value was used for all further experiments. Further working solutions were made by dilution 
of the approximate 700ng/mL solution 1:5 to make a 140ng/mL solution, and then serial diluting 
to obtain solutions with the following concentrations: 70, 35, 18, 8.8, 4.4 and 2.2 ng/ml. 
 125µL of each of the working solutions was added to 1:1 ultrapure water: acetonitrile solution 
(240µL). An aliquot of 90% formic acid (25µL) was then added to precipitate plasma proteins and 
deactivate enzymes that may contribute to the degradation of the curcuminoids, and 50mM 
ascorbic acid (100µL) was added to prevent the oxidation of the curcuminoids in the sample. 
Plasma from a WT, control-fed mouse (10µL) was also added to account for the matrix effect. 
These standard solutions resulted, therefore, in a curcuminoid concentration ¼ of that of the 
original working solution e.g. a 35 ng/mL working solution resulted in an 8.8 ng/mL curcuminoid 
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standard solution, where the following standard solution concentrations were obtained: 35, 18, 8.8, 
4.4, 2.2, 1.1 and 0.55 ng/mL. 
 
3.3.2.3 Sample preparation 
For each dosage group, mouse plasma (10.0µL) was added to a 1:1 ultrapure water: acetonitrile 
solution (280µL) and 50mM ascorbic acid (10µL) in each of six centrifuge tubes. For each dosage, 
three mice were tested in triplicate (a total of nine repeat measurements per experimental dosage). 
Three of the six samples were treated with β-Glucuronidase (100µL, ≥ 90,000 units, in aqueous 
solution), containing both the glucuronidase and sulfatase enzyme derived from the Roman snail, 
Helix pomatia, (resultant pH of solution ~5.5) to recover the parent compounds of conjugated 
curcuminoids (enzyme treated samples), and for the other three samples (untreated samples), 
100µL of 1:1 ultrapure water: acetonitrile solution was added. All samples were vortexed for 20 
seconds, after which the enzyme treated samples were incubated for 1 hour at 37°C. After 
incubation, 90% formic acid (50.0µL) and 1:1 ultrapure water: acetonitrile solution (50µL) was 
added to each sample. 
 
3.3.2.4 Extraction and UPLC-MS/MS preparation 
For both standard and sample solutions, curcuminoids were extracted initially using 1.00mL ethyl 
acetate, vortex-mixed for 20 seconds, and then centrifuged for 10 minutes at 12,000g with a 
chamber temperature of 6°C. Extraction was repeated another two times, after which the pooled 
supernatant was evaporated using a Christ AVC 2-25 CD speedivac at 45°C until dry. 
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The resin was reconstituted in 1.00mL of 1:1 ultrapure water: acetonitrile, and placed into a 2mL 
chromatography sample vial. The highest dosage plasma samples (140mg/kg.bw/day, Meriva® 
formulation) were diluted 1:2 with 50% aqueous acetonitrile in order for the concentration of these 
samples to remain within the calibration curve range. 
 
3.3.2.5 UPLC-MS/MS instrument set-up 
Chromatographic analysis of curcuminoids was performed on a Waters Acquity UPLC System 
(Milford MA USA), fitted with a binary solvent manager and sample manager thermostatted to 4°. 
An Acquity UPLC HSS C18, 1.8um, 2.1x150mm column was used, with a flow rate of 0.2mL/min. 
The column temperature remained at 35°C during analysis.  
A gradient elution was used to achieve chromatographic separation, as outlined in Table 3, with 
Solvent A consisting of 0.1% formic acid in ultrapure water, and Solvent B consisting of 0.1% 
formic acid in LC-MS grade acetonitrile. A 10.0 µL aliquot of each sample was injected into the 
system in full loop mode (automatic sample loop overfill), with a total run time of 20 minutes per 
sample. 
Mass spectrometric detection of curcuminoids was achieved using a Waters Xevo TQ-MS triple 
quadrupole mass spectrometer (Wilmslow, UK) using electrospray ionisation in positive ion mode. 
Source parameters were set as follows: capillary voltage 2.00 kV, source temperature 150°C, 
desolvation temperature 350°C, desolvation gas (N2) flow 400 L/h, cone gas (N2) 0 L/h, and 
collision gas (Ar) flow 0.15 mL/min. Multiple reaction monitoring (MRM) transitions, dwell, cone 
voltage and collision voltage outlined in Table 4.  
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Table 3. Gradient conditions set for UPLC-MS/MS analysis. Gradient conditions are set out for analysis of 
mouse plasma, with Solvent A containing 0.1% formic acid in ultrapure water, and Solvent B containing 0.1% 
formic acid in acetonitrile 
Time (min) Flow rate 
(mL/min) 
% Solvent A % Solvent B Curve 
0 2 55 45 Initial 
6 2 43 57 6 
7 2 0 100 6 
15 2 55 45 11 
20 2 55 45 11 
 
 
Table 4. MRM transitions for the determination of curcuminoids in mouse brain tissue and plasma with 
UPLC-MS/MS 
Compound Parent 
ion (m/z) 
Daughter 
ion (m/z) 
Dwell 
(s) 
Cone 
Voltage 
(V) 
Collision 
Voltage 
(V) 
Curcumin 369.2873 117.0585 0.022 23 46 
369.2873 145.0441 0.022 23 32 
369.2873 177.0619 0.022 23 22 
Demethoxycurcumin 339.2542 147.0214 0.022 24 26 
339.2542 177.0277 0.022 24 22 
339.2542 255.0801 0.022 24 16 
Bisdemethoxycurcumin 309.2342 119.0170 0.022 27 38 
309.2342 147.0034 0.022 27 24 
309.2342 225.0878 0.022 27 16 
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3.3.2.6 System suitability checks and method validation 
A number of system suitability checks and validation experiments were performed to assess the 
suitability of the current method. These include: 
1. Generation of a calibration curve used seven reference points, plus a blank sample. The 
concentration of curcuminoids used in the calibration curve was 0, 0.547, 1.094, 2.188, 
4.375, 8.75, 17.50 and 35.00 ng/mL, respectively. Samples for linearity determination were 
prepared in the same fashion as the experimental standards outlined above. We aimed to 
achieve a coefficient of determination (R2) value above 0.995. 
2. Determination of lower limit of detection (LLOD) and lower limit of quantification 
(LLOQ) were calculated as 3x the standard deviation of the response (AUC) of the lowest 
concentration standard (0.547ng/mL) divided by the slope of the calibration line, and 10x 
the standard deviation of the response (AUC) of the lowest concentration standard divided 
by the slope of the calibration line, respectively. Standard deviation was calculated from 
10 injections of the lowest concentration standard. 
 
Example calculation: 
Calibration curve equation: Y = 273.4X – 26.10 
Standard deviation of 10 injections of 0.547 ng/mL (AUC) = 29.68 
LLOD = 3 x 29.68 ÷ 273.4 
            = 0.33 ng/mL 
LLOQ = 10 x 29.68 ÷ 273.4 
 33 
 
           = 1.09 ng/mL 
 
3. A spiking experiment where plasma samples were “spiked” with known concentrations of 
curcuminoids in order to assess the matrix effect. The spiked curcuminoid concentrations 
were 0, 0.547, 1.094, 2.188, 4.375, 8.75, 17.50 and 35.00 ng/mL. Both spiked and solvent 
standards were prepared in the same manner as the experimental standards, outlined above. 
However, as the solvent standards did not contain any plasma, an extra 10µL of 1:1 
ultrapure water: acetonitrile solution was added in compensation. 
 
3.3.2.7 Data analysis 
Data were analysed using MassLynx software, version 4.1. Figures were produced within the 
Masslynx software, as well as Microsoft Office Excel, Professional Plus 2016 and Prism 
(Graphpad), Version 7. HPLC/MS sample analysis was conducted over a two-day period. For each 
day, a separate calibration curve was created. Calibration curves for each curcuminoid (prepared 
using spiked plasma samples) on both days are included in Appendix A.  AUC raw data for 
curcuminoid concentration in mouse plasma is included in Appendix B. Data tables for 
curcuminoid plasma concentration may be found in Appendix C, which will detail which plasma 
concentration corresponds with each calibration curve. 
Free curcumin concentration in plasma was determined to be the calculated concentration in 
samples which were not treated with enzymes i.e. conjugates remained intact and therefore were 
not included in concentration measurements. The total conjugate concentration for each 
curucminoid was calculated as the total concentration of enzyme treated samples (where parent 
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curcuminoids were recovered from conjugated curcuminoids), minus free curcumin concentrations 
for that sample. All AUC values reported combine enol- and keto- forms of each curcuminoid. 
 
3.4 Methods for Aim 3 
To determine the efficacy of apigenin after long term feeding (from 3 months of age) in being able 
to improve motor function, learning, spatial awareness and memory in GFAP-IL6 transgenic mice. 
 
3.4.1 Cohort information and animal housing 
In the present study, a total of four cohorts (Table 5) will be examined in a range of behavioural 
tests aiming to assess the cognitive abilities and motor skills of the mice. 
Cohorts 2 and 4 were fed mouse chow pellets containing 400mg/kg of apigenin from 3 months of 
age, and the additional two cohorts (cohorts 1 and 3) were fed control mouse chow pellets 
containing no apigenin from the same age. In light of variable and limited behavioural efficacy 
observed in the literature for lower food concentrations, this study opted to use a higher 
concentration of 400mg/kg of apigenin in the mouse chow pellets. The age of the mice at the time 
of testing ranges from 19 months to 23 months old. Cohort 1 consisted of a total of 12 mice; seven 
males and five females. Seven mice were tested for Cohort 2 (five male, two female), nine mice 
for Cohort 3 (seven male, two female), and 14 mice for cohort 4 (six male, eight female). The mice 
were previously tested at in walking beam, accelerod and Barnes maze at 8 months of age after 
being fed with the apigenin feed for 5 months, and the survivors were retested in the following 
experiment. 
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Table 5. Cohort information for apigenin behavioural experiments 
 
 ID GENOTYPE SEX AGE AT 
TIME OF 
TEST 
Cohort 1 
(GFAP-IL6, 
control-fed + 
1x WT, control 
fed) 
2535 GFAP-IL6 M 21 MO 
2536 GFAP-IL6 M 21 MO 
2537 GFAP-IL6 M 21 MO 
2539 GFAP-IL6 M 21 MO 
2540 GFAP-IL6 M 21 MO 
2541 GFAP-IL6 M 21 MO 
2630 GFAP-IL6 M 21 MO 
2354 GFAP-IL6 F 22 MO 
2355 GFAP-IL6 F 22 MO 
2356 GFAP-IL6 F 22 MO 
2544 GFAP-IL6 F 21 MO 
2545 WT F 21 MO 
Cohort 2 
(GFAP-IL6, 
apigenin-fed) 
2349 GFAP-IL6 M 23 MO 
2350 GFAP-IL6 M 23 MO 
2497 GFAP-IL6 M 22 MO 
2498 GFAP-IL6 M 22 MO 
2499 GFAP-IL6 M 22 MO 
2501 GFAP-IL6 F 22 MO 
2504 GFAP-IL6 F 22 MO 
Cohort 3  
(WT, control-
fed) 
3406 WT M 20 MO 
3408 WT M 20 MO 
3409 WT M 20 MO 
3410 WT M 20 MO 
3411 WT M 20 MO 
3412 WT M 20 MO 
Not recorded  WT M 20 MO 
3416 WT F 20 MO 
3502 WT F 19 MO 
Cohort 4  
(WT, apigenin-
fed) 
 
 
 
 
 
3161 WT F 23 MO 
3160 WT F 23 MO 
3226 WT M 23 MO 
3227 WT M 22 MO 
3228 WT M 22 MO 
3407 WT F 20 MO 
3413 WT F 20 MO 
3414 WT F 20 MO 
3415 WT F 20 MO 
3501 WT M 20 MO 
3514 WT F 20 MO 
3515 WT F 20 MO 
3594 WT M 19 MO 
3595 WT M 19 MO 
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The mice were bred and kept at the animal house, located at the School of Medicine, Western 
Sydney University. Their housing environment was temperature regulated, with a normal 12:12 hr 
light-dark cycle. The mice had free access to food and water during the testing period. 
 
3.4.2 Mouse handling 
The first three days of the testing period were set aside for handling the mice, in order to acclimate 
the mice to being handled, with the aim of reducing anxiety during testing. The level of interaction 
between the mouse and the handler was increased slowly in accordance with the following 
procedure: 
Day 1: The lid of the home cage and the food grill was removed and set aside. The cage was then 
left undisturbed for 60 seconds. The gloved hand of the handler was placed in one corner of the 
home cage for 60 seconds, and the mice in the cage are allowed the freely sniff the hand during 
this time. The handler then moved any enrichment material (such as a tunnel, or shredded 
cardboard) gently around the cage. Each mouse was then picked up briefly by the tail for 3-4 
seconds and placed gently back in the home cage. 
Day 2: The lid of the home cage and the food grill was removed and set aside. The cage was then 
left undisturbed for 30 seconds. The gloved hand of the handler was then placed in one corner of 
the home cage for 30 seconds, and the mice in the cage were allowed to freely sniff the hand during 
this time. The handler then moved any enrichment material placed in the cage around gently. Each 
mouse was then picked up briefly by the tail for 3-4 seconds, placed in an empty cage containing 
no materials for 10 seconds, and then placed gently back in the home cage. This last step was 
completed 5 times for each mouse. 
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Day 3: The lid of the home cage and the food grill were removed and set aside. The cage was then 
left undisturbed for 15 seconds. The gloved hand of the handler was placed in one corner of the 
home cage for 15 seconds, and the mice in the cage were allowed the freely sniff the hand during 
this time. The handler then removed all enrichment material from the cage. Each mouse was then 
picked up briefly by the tail for 3-4 seconds, placed in an empty cage containing no materials for 
5 seconds, picked up by the tail and placed on the handlers’ arm for 5 seconds before being placed 
back in the home cage. This last step was completed 7 times for each mouse. The test mice were 
then transported (on a trolley, with cages covered by lab coats) to the testing room and left to 
habituate for 60 minutes, before being returned to the animal facility. 
 
3.4.3 Physical battery  
A number of physical battery tests were conducted over a single day of testing. The physical 
battery tests investigate the general health and functional motor activity of the test mice in order 
to determine their suitability and capability for the subsequent behavioural testing. The weights of 
all mice were recorded and analysed to detect possible skeletal muscle atrophy in the transgenic 
mice in comparison to WT mice, as well as determining if there may be a taste bias between control 
fed and apigenin fed mouse chow. Functional motor activity aims to give an initial assessment of 
the motor capabilities of the test mice. Test parameters included the level of kyphosis (abnormal 
spinal curvature), gait, ledge balance and hindlimb clasping, which were assessed and scored (a 
lower score equates to better performance in the test), which, grouped together, give an overall 
assessment of the motor capabilities of the mice. The sum of scores for each of the functional 
motor activity parameters (composite score) was recorded for analysis. Further information 
regarding the protocols and test parameters can be found in Appendix D1. 
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3.4.4 Walking beam 
The walking beam (Fig 6) test was conducted over a 3-day period, and aimed to assess the balance 
and motor coordination of the mice. On each given day, the mice were subjected to 3 trials whereby 
the home cage was placed on one end of the apparatus. The mouse was placed behind the red line 
on the other end, and the length of time taken (in seconds) to traverse the beam was recorded. On 
the third day of trials, the number of times the mouse’s hindlimbs slipped off the balance beam 
(known as “foot slips”) was also recorded. Between each trial, the apparatus was cleaned 
thoroughly with 70% ethanol and allowed to fully dry before the beginning of the subsequent test. 
The mean of the three trials on the test day was considered for analysis. All tests were video 
recorded, so that the test was able to be reviewed at a later stage. Further information regarding 
the protocols and test parameters can be found in Appendix D2. 
 
 
Fig 6. Walking beam apparatus. The walking beam apparatus was used to test motor skills and balance in apigenin 
fed and control fed GFAP-IL6 and WT mice. 
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3.4.5 Accelerod 
The aim of the accelerod (Fig 7) test is to investigate the level of balance and motor coordination 
of the mice. The experiment involved placing a mouse on a rotating rod that slowly increased in 
speed from 0 rpm to 40 rpm over a maximum period of 300 seconds. The mice were placed facing 
the opposite direction to the rotation of the rod, so that the mice must continue to walk in order to 
remain on the accelerod. This was a single day test, and mice were given three trials, with a 30-
minute resting period between each trial. Between each trial, the apparatus was cleaned thoroughly 
with 70% ethanol and allowed to fully dry before the beginning of the subsequent test. The duration 
the mice were able to remain on the accelerod, as well as the percentage of total time the mice 
spent in passive rotation i.e. no movement of the paws while the rod was rotating, was recorded 
for analysis. In addition to assessing the motor skills of the mice, analysing the time spent in 
passive rotation may also give an indication of the level of fatigue, motivation and strength of the 
mice. The mean of the three trials on the test day was considered for analysis. All trials were video 
recorded, so that the test could be reviewed at a later stage. Further information regarding the 
protocols and test parameters can be found in Appendix D3. 
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Fig 7. The accelerod apparatus. The accelerod apparatus was used to test motor skills balance in apigenin-fed and 
control-fed GFAP-IL6 and WT mice. A maximum of 4 mice were tested at any one time, and were placed between 
the brown circular barriers, facing the black curtain in the background. 
 
3.4.6 Barnes maze 
The Barnes maze (Fig 8) employs the use of a suspended circular platform with 20 evenly spaced 
holes; 19 of which are “fake” holes, and one of which is an “escape hole”. The Barnes maze aims 
to assess the learning and memory of the mouse by ascertaining if a mouse is able to remember 
the location of the “escape hole” through the use of inter-maze cues (placement of cards containing 
a different shape at every 5th hole – as seen in Fig 8) and intra-maze cues (for example, a fire 
hydrant on a wall or a cluster of furniture). The mouse is motivated to enter the hole through the 
use of various aversive stimuli: an open-field, binaural beats played at 85 dB, and bright lights (95 
lux).  
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Fig 8. The Barnes Maze apparatus. The Barnes maze apparatus aimed to test the spatial awareness and learning 
capabilities of apigenin fed and control fed GFAP-IL6 and WT mice 
 
Using the ANY-maze (Stoelting) software version 4.99, the platform was divided into a number 
zones (Fig 9) which aided analysis in terms of analysing search patterns of the mice. 
The testing period lasted 4 days in total. The first day of testing- the habituation trial (one trial), 
aimed to introduce the test apparatus to the mouse and after 20 seconds on the apparatus, the 
handler gently guided the mouse to the escape hole. The following two days, during the acquisition 
trials (three trials per day), the mouse was allowed to roam around the apparatus freely, and was 
only guided to the “escape hole” if the mouse had not entered the hole within the testing period 
(180 seconds). Once the mouse entered the hole during the trial, the lights and sound were switched 
off, and the mouse was left undisturbed for 2 minutes during the habituation, as well as on the first 
day of the acquisition trial, and for 1 minute on the second day of the acquisition trial. A 72-hour 
rest period was then given between the acquisition trials and the last trial – the probe trial. During 
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the probe trial, the “escape hole” was swapped with a “fake” hole, and the mouse was allowed to 
roam the apparatus for 90 seconds. The “escape hole” was removed in the probe trial to determine 
how “insistent” the mouse was regarding the location of the “escape hole” that was present in 
previous trials i.e. an indication of true learning. Between each trial, the apparatus was cleaned 
thoroughly with 70% ethanol and allowed to fully dry before the beginning of the subsequent test. 
Test parameters investigated for Barnes maze included primary latency (latency until first visit to 
the escape hole), primary path length (path length prior to first visit to the escape hole), primary 
errors (the number entries to holes other than the escape hole prior to initial entry to the escape 
hole), total latency (latency until complete entry to the escape hole), total path length (path length 
over the test period), total errors (the number entries to holes other than the escape hole over the 
test period), the number of head entries made to the escape hole over the test period, and the total 
time spent in each of four quadrants. For each parameter, we distinguished between learning 
(analysis of the six acquisition trials) and memory (analysis of the probe trial, after a 72-hour rest 
period). Memory assessment also included observing the total time the mice spent in each of the 
four quadrants during the probe trial. Further detail regarding the Barnes maze protocol used in 
our laboratory can be found in Appendix D4. 
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Fig 9. Division of the Barnes maze apparatus into zones. The ANY-Maze software detected the mouse on the video 
feed, and relayed information regarding the location of the mouse in the corresponding zone. The platform is divided 
primarily into four quadrants (Q1, Q2, Q3 and Q4), which is then sub-divided into a ‘centre’ zone and the areas of 
each quadrant containing the holes (Q1b, Q2b, Q3b and Q4b). The escape hole, located in Q3 is indicated in red. 
 
3.4.7 Data collection and analysis  
Barnes maze data was recorded using ANY-maze (Stoelting) software version 4.99. For all other 
behavioural tests, data was recorded using a Sony camcorder, model: HDR-CX130E. The 
experimental data was analysed using Prism (GraphPad) software, version 7, and in IBM SPSS 
Statistics Version 24. For all behavioural testing analysis, 3 variables were considered for each test 
parameter; diet (control fed vs. apigenin fed), genotype (WT vs GFAP-IL6), and sex (male vs. 
female). As such, three-way ANOVAs were completed to determine any main effects of the 
variables, as well as interactions, between groups, for each test parameter (significance: p <0.05). 
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Two-way ANOVAs were also performed for each sex, investigating possible significant diet and 
genotype effects, and interactions (significance: p <0.05). For Barnes maze analysis, repeated 
measures ANOVAs were completed (two-way and three-way) as different time points (over 
training days, and testing day) were also considered. In repeated measures ANOVAs, both between 
group trends (how did each group perform in comparison to one another?) and within group trends 
(did learning over the six acquisition trials occur for that particular group?) were conducted. The 
data were split by sex given that in some test parameters, a sex effect was observed with grouped 
male and female analysis (see section 5.1).  
 
 
 
 
 
 
 
 
 
 
 45 
 
4. Results (Meriva® curcumin project) 
4.1 Determination of combined curcuminoid content in mouse chow pellets 
Curcumin concentration in mouse chow pellets was determined using spectrophotometry, with the 
purpose of confirming the expected curcumin concentrations that had been added to the chow 
during the manufacturing process. We speculated that if the experimentally determined 
concentrations were matching or close to the expected concentrations, the mice used in subsequent 
experiments would be able to consume the experimental doses of curcumin, as set out in Table 6. 
Since curcumin, demethoxycurcumin and bisdemethoxycurcumin are indistinguishable by UV-vis 
spectrophotometry, an assumption was made that the molar attenuation coefficients for these 
species were identical. 
The results for curcumin mouse chow analysis are set out in Table 6. Mean concentration, 
calculated from absorbance values and the Beer-Lambert law, increased proportionally to the mass 
of curcumin per kilogram that was added to the chow. For the 35 and 70mg/kg.bw/day Meriva® 
groups, as well as the 140 mg/kg.bw/day naïve curcumin group, the percentage extraction of 
curcumin obtained was approximately 90%, indicating that the mice consuming these chow pellets 
are expected to have ingested close to the corresponding experimental doses. However, for the 140 
mg/kg.bw/day Meriva® group formulation, the percentage extraction dropped to approximately 
78%.  
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*Mass of curcumin/kg excluding the weight of the phytosome. Naïve curcumin is not encapsulated in a phytosome. 
 
This assay was not designed to be a highly accurate quantification of the concentration of each of 
the three curcuminoids, but rather an indication that the nominal concentrations and the dose ratios 
were approximately correct and valid for the feeding experiments. 
 
4.2 Curcuminoid concentration in plasma 
Plasma concentrations of curcuminoids were tested in GFAP-IL6 mice to determine, firstly, if the 
Meriva® curcumin, a phosphatidylcholine formulation, was able to improve bioavailbiility of 
curcuminoids and/or conjugates in comparison to naïve curcumin (low bioavailability control). 
Secondly, we wanted to quantify plasma levels of Meriva® curcumin in a GFAP-IL6 mouse model 
of neuroinflammation, representing the first stage of determining the efficacy of Meriva® 
curcumin as a potential treatment of neuroinflammation. 
 
Dosage of chow 
(g/kg.bw/day) 
Mass 
curcumin/kg 
(g)* 
Mean 
Absobance ±SE 
(AU) 
Mean 
Concentration ±SE 
(g/kg) 
% 
Extraction 
0 (Control) 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 
35 (Meriva®) 0.22 0.48 ± 0.03 0.19 ± 0.01 88.2 
70 (Meriva®) 0.44 0.97 ± 0.05 0.39 ± 0.02 88.4 
140 (Meriva®) 0.87 1.68 ± 0.03 0.68 ± 0.01 77.7 
140 (Naïve) 0.87 1.95 ± 0.00 0.78 ± 0.00 90.2 
Table 6. Mean absorbance, concentration data and % extraction for extraction of curcuminoids from 
mouse pellets using methanol (λ max 421-422nm) 
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4.2.1 Separation of analytes and linearity of the detector response 
As shown in Fig 10, the developed liquid chromatography (LC) method was able to separate the 
analytes effectively. Two peaks were identified for each curcuminoid in the chromatogram, which 
represent keto-enol tautomers of each of the curcuminoids. Peak shape is sharp, narrow and 
symmetrical, with limited distortions which contributed to higher accuracy and precision of our 
results in this study.  
 
  
Fig 10. Overlayed chromatograms of standard solutions of curcumininoids. Chromatograms are shown for 
curcumin (C), demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) using a gradient elution with solvent 
(A) 0.1% formic acid in ultrapure water, and Solvent (B) 0.1% formic acid in acetonitrile. Analytes were separated 
using an Acquity UPLC HSS C18, 1.8um, 2.1x150mm column. Keto tautomers of all curcuminoid elute from the 
colums first, followed by enol tautomers (126) 
 
The UPLC-MS/MS detector response for all three curcuminoids was found to be linear between 0 
and 35ng/mL (Fig 11 A-C). Correlation coefficient values were 0.9993 for curcumin (A), 0.9995 
for demethoxycurcumin (B), and 0.9994 for bisdemethoxycurcumin (C).  
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Fig 11 (A-C). Linearity of the detector response for curcuminiods. Linearity is shown for curcumin (A), 
demethoxycurcumin (B) and bisdemethoxycurcumin (C) in 1:1 ultrapure water:acetonitrile, spiked with 10µL of 
control fed, WT mouse plasma 
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4.2.2 Limits of detection and quantification 
LLOQ and LLOD values for all curcuminoids are presented in Table 7. Curcumin was unable to 
be reliably quantified below 0.76 ng/mL, and was deemed to be undetectable at calculated 
concentrations below 0.23 ng/mL. The lowest concentration of demethoxycurcumin that could be 
reliably quantified was 0.68 ng/mL, with the detectable limit set at 0.20 ng/mL. The LLOQ and 
LLOD for bisdemethoxycurcumin was 1.13 ng/mL and 0.34 ng/mL, respectively. 
 
Table 7. Calculated LLOQ and LLOD values for curcumin, demethoxycurcumin and bisdemethoxycurcumin. 
 Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
Mean AUC (±SE) of 10 injections 
of 0.547ng/mL 
 
145.1 ± 10.0 208.5 ± 10.7 163.9 ± 18.6 
SD of 10 injections of 
0.547ng/mL (AUC) 
 
31.66 
 
33.97 
 
58.78 
 
Slope of the calibration line 
 
 
415.8 497.7 518.4 
LLOQ (ng/mL) 
 
 
0.76 0.68 1.13 
LLOD (ng/mL) 
 
 
0.23 0.20 0.34 
 
 
4.2.3 Recovery of curcuminoids from spiked plasma 
In the present experiment, the response of curcuminoid spiked solvent standards (containing no 
plasma) was compared with the response of spiked plasma standards (spiked with both 
curcuminoids and 10.0µL of plasma) to assess matrix effects with the addition of plasma matrix. 
For all curcuminoids, the AUC measured for spiked plasma standards was substantially lower than 
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for solvent standards (Fig 12, A-C), indicating possible matrix suppression. Curcumin was unable 
to be reliably quantified for samples spiked with 1.094ng/mL and below, however, from 
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Fig 12 (A-C). Calibration curves comparing peak integration counts (AUC) of solvent standards and standards 
spiked with 10µL of control fed mouse plasma (concentration range = 0-35ng/mL). Calibration curves are shown 
for curcumin (A), demethoxycurcumin (B), and bisdemethoxycurcumin (C). R square values and equations are 
representative of linearity for solvent standards.  
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2.188 ng/mL to 35 ng/mL, calculated concentrations of spiked plasma deviated from expected 
concentrations, ranging from 38-52% below the original spiking concentration (Table 8). 
 
Table 8. Percentage deviation of mean calculated concentration from spiked concentration for curcumin 
Spiking concentration 
(ng/mL) 
Mean AUC 
±SE 
Mean calculated concentration ±SE 
(ng/mL) 
% Deviation 
0 
 
7.46 ± 2.87 0.33 ± 0.00 +0.33 
0.547 
 
81.4 ± 4.04 0.46 ± 0.00 -16.13 
1.094 
 
211 ± 27.8 0.68 ± 0.05 -37.77 
2.188 
 
447 ± 13.8 1.09 ± 0.02 -50.35 
4.375 
 
1214 ± 85.3 2.40 ± 0.15 -45.12 
8.75 
 
2518 ± 134 4.64 ± 0.23 -52.23 
17.5 
 
4810 ± 48.1 8.57 ± 0.08 -51.03 
35 
 
11661 ± 252 20.32 ± 0.43 -41.64 
 
Similarly, demethoxycurcumin concentrations were determined to be below LLOQ for samples 
spiked with 1.094ng/mL and below, while the deviations from the spiked concentrations of 2.188 
ng/mL to 35 ng/mL ranged from 45-59% below the expected concentration (Table 9). 
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Table 9. Percentage deviation of mean calculated concentration from spiked concentration for 
demethoxycurcumin. 
 
 
Spiked plasma concentrations for bisdemethoxycurcumin (Table 10) fell below LLOQ for samples 
spiked with 2.188 ng/mL, and could not be detected in samples spiked with 1.094 ng/mL. Samples 
spiked with 0.547 ng/mL produced a negative value concentration, indicating the actual 
concentration of the sample was below the threshold of the calibration curve. 
Bisdemethoxycurcumin concentration in plasma samples spiked with 4.375ng/mL and above were 
found to be 63-71% below the expected spiked concentrations. 
 
 
 
 
 
 
 
 
 
 
Spiking concentration (ng/mL) Mean AUC ±SE Mean calculated concentration 
±SE (ng/mL) 
% Deviation 
0 
 
3.52 ± 1.96 0.08 ± 0.00 +0.08 
0.547 
 
66.7 ± 25.9 0.18 ± 0.04 -67.50 
1.094 
 
257 ± 45.2 0.45 ± 0.07 -58.50 
2.188 
 
566 ± 55.2 0.90 ± 0.08 -58.77 
4.375 
 
1360 ± 81.6 2.05 ± 0.12 -53.04 
8.75 
 
2944 ± 108 4.35 ± 0.16 -53.36 
17.5 
 
5976 ± 42.8 8.75 ± 0.06 -49.99 
35 
 
13197 ± 209 19.23 ± 0.30 -45.06 
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Table 10. Percentage deviation of mean calculated concentration from spiked concentration for 
bisdemethoxycurcumin. 
 
 
 
Standard curves for solvent standards, used to calculate spiked standard concentration, were linear 
for all curcuminoids between 0 and 35 ng/mL. Correlation coefficient values were 0.9933 for 
curcumin, 0.9987 for demethoxycurcumin and 0.9993 for bisdemethoxycurcumin (Fig 12, A-C). 
 
4.2.4 Determination of curcuminoid and conjugate concentrations in mouse plasma 
In this experiment, LC-MS/MS was used to determine both free curcuminoid concentrations, and 
conjugate concentrations (sulfates and glucuronides). To measure conjugate concentrations, 50% 
of samples were treated with the enzyme β-Glucuronidase, containing both the glucuronidase and 
sulfatase enzyme derived from the Roman snail, Helix pomatia. This serves the purpose of 
cleaving a sulfo group (for curcumin sulfate) or glucuronic acid (for curcumin glucuronide) from 
the parent compound, which is then able to be detected using LC-MS/MS (Fig 13). The other 50% 
of samples were left untreated (to determine free curcuminoid concentration only), and the 
Spiking concentration (ng/mL) Mean AUC ±SE Mean calculated concentration 
±SE (ng/mL) 
% 
Deviation 
0 
 
0 0 0 
0.547 
 
142 ± 14.2 -0.09 ± 0.01 -116.62 
1.094 
 
235± 37.8 0.002 ± 0.04 -99.85 
2.188 
 
752 ± 148 0.64 ± 0.09 -76.48 
4.375 
 
1621 ± 102 1.50 ± 0.10 -68.50 
8.75 
 
3066 ± 253 2.93 ± 0.15 -71.15 
17.5 
 
5965 ± 102 5.81 ± 0.10 -67.48 
35 
 
13330 ± 207 13.12 ± 0.21 -62.84 
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concentration of untreated samples was then subtracted from the concentration of treated samples 
to determine conjugate concentration. 
 
 
Fig 13. Curcumin glucuronide (II) and curcumin sulfate (III) molecules. The enzyme β-Glucuronidase, containing 
both the glucuronidase and sulfatase enzyme derived from the Roman snail, Helix pomatia, is used to cleave either a 
glucuronic acid (in the case of curcumin glucuronidase) or a sulfo group (in the case of curcumin sulfate), . The section 
of the molecule which is cleaved is highlighted within the red circles. Source: Vareed et al 2014, Cancer Epidemiology, 
Biomarkers & Prevention, 17, 1411-1417 (60) 
 
4.2.4.1 Curcumin 
As expected, free curcumin was not detected in control fed WT and GFAP-IL6 groups (Table 11). 
However, for mouse plasma from the 35, 70 and 140 mg/kgbw/day Meriva® groups, although 
detected, calculated free curcumin concentrations remained below LLOQ. The low bioavailability 
control, the 140mg/kg.bw/day naïve curcumin dosage group, had the only quantifiable levels of 
curcumin at 114 ng/mL of plasma. 
Curcumin conjugates (sulfates and glucuronides) were detectable and quantifiable in all Meriva® 
and naïve curcumin groups, and either below LLOQ or LLOD in control fed WT and GFAP-IL6 
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groups (Table 11). A dose-response relationship was observed between Meriva® curcumin dose 
and plasma concentration. Conjugate concentration in plasma nearly doubled between the 
35mg/kg.bw/day Meriva® and the 70mg/kg.bw/day groups, from 513 ng/mL to 985 ng/mL, and 
again between the 70mg/kg.bw/day group and the 140mg/kg.bw/day group, from 985 ng/mL to 
1749 ng/mL. Curcumin plasma concentration for 140mg/kg.bw/day naïve curcumin dosage group 
was calculated to be slightly below that of the 70 mg/kg.bw/day Meriva® group, at 916 ng/mL. 
 
4.2.4.2 Demethoxycurcumin 
Free demethoxycurcumin plasma concentrations are presented in Table 12. In both control-fed WT 
and GFAP-IL6 mouse plasma, free demethoxycurcumin was detected, but at levels below LLOQ. 
Similarly, plasma concentration in the 70 to 140 mg/kg.bw/day Meriva® groups, as well at the 
140 mg/kg.bw/day naïve curcumin group, was calculated to be below LLOQ. Demethoxycurcumin 
was not detected in the plasma of the 35 mg/kg.bw/day Meriva® group. 
Demethoxycurcumin conjugates were detected in both control-fed WT and GFAP-IL6 groups, as 
well as the 35 and 70 mg/kg.bw/day Meriva® groups. However, in all the aforementioned groups, 
all calculated concentrations fell below LLOQ. Demethoxycurcumin conjugate plasma 
concentration was slightly higher in the 140 mg/kg.bw/day Meriva® group than the 140 
mg/kg.bw/day naïve curcumin group, at 162 ng/mL and 106 ng/mL, respectively. 
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4.2.4.3 Bisdemethoxycurcumin 
Neither free, nor conjugated bisdemethoxycurcumin were detected in any of the dosage groups 
(Table 13). Given the low concentrations present in the mouse chow pellets (5-10% of total 
curcuminoid content), this result is not unexpected.
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Table 11. Area data, obtained from LC/MS analysis, and calculated plasma concentration of curcumin in Meriva® fed and naïve curcumin fed mice*. 
* Raw data presented in Appendix B 
**Expected AUC taking into account any dilution of samples  
***Mean concentration calculated in 1mL of 1:1 ultrapure water: acetonitrile. Free curcumin concentrations were deducted from total curcumin concentrations 
(if concentrations > LLOQ) to calculate conjugates  
**** Mean concentration calculated in 10µL of plasma in each sample x1
Curcumin Dosage 
(mg/kg.bw/day), 
Formulation 
Mouse 
Genotype 
Fed 
Mean AUC 
±SE 
Standardised 
Mean AUC** 
Mean Concentration 
±SE (ng/mL in 
sample)*** 
Mean Concentration  
(ng/mL in 
plasma)**** 
Free curcumin 0 
 
WT 2.87 ± 2.87 2.87 0.07 ± 0.08 7 
0  
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0 
35, Meriva® 
 
GFAP-IL6 11.05 ± 4.92 11.05 0.26 ± 0.16 26 
70, Meriva® 
 
GFAP-IL6 26.95 ± 9.22 26.95 0.33 ± 0.12 33 
140, Meriva® 
(1:2 dilution) 
GFAP-IL6 36.24 ± 7.76 72.48 0.41 ± 0.10 41 
140, naïve 
(unformulated) 
GFAP-IL6 257.77 ± 85.64 257.77 1.14 ± 0.33 114 
Curcumin 
conjugates 
(sulfates/ 
glucuronides) 
0  
 
WT 18.94 ± 9.47 18.94 0.27 ± 0.13 27 
0  
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0 
35, Meriva® 
 
GFAP-IL6 1192 ± 101 1192 5.13 ± 0.53 513 
70, Meriva® 
 
GFAP-IL6 2361 ± 178 2361 9.85 ± 1.04 985 
140, Meriva® 
(1:2 dilution) 
GFAP-IL6 2643 ± 110 5286 17.49 ± 0.34 1749 
140, naïve 
(unformulated) 
GFAP-IL6 3152 ± 289 3152 9.16 ± 0.89 916 
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Table 12. Area data, obtained from LC/MS analysis, and calculated plasma concentration of demethoxycurcumin in Meriva® fed and naïve curcumin fed mice*.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Raw data presented in Appendix B 
**Expected AUC taking into account any dilution of samples  
***Mean concentration calculated in 1mL of 1:1 ultrapure water: acetonitrile. Free curcumin concentrations were deducted from total curcumin concentrations (if 
concentrations > LLOQ) to calculate conjugates  
**** Mean concentration calculated in 10µL of plasma in each sample x100  
Demethoxycurcumin Dosage 
(mg/kg.bw/day), 
formulation 
Mouse 
genotype 
Fed 
Mean AUC ±SE Standardised 
AUC** 
Mean Concentration 
±SE (ng/mL in 
sample)*** 
Mean Concentration 
(ng/mL in 
plasma)**** 
Free demethoxycurcumin 0 
 
WT 2.04 ± 1.19 2.04 0.42 ± 0.11 42 
0  
 
GFAP-IL6 0.78 ± 0.21 0.78 0.63 ± 0.00 63 
35, Meriva® 
 
GFAP-IL6 0.42 ± 0.29 0.42 0.14 ± 0.09 14 
70, Meriva® 
 
GFAP-IL6 0.54 ± 0.34 0.54 0.21 ± 0.11 21 
140, Meriva® 
(1:2 dilution) 
GFAP-IL6 4.66 ± 3.27 9.32 0.22 ± 0.13 22 
140, naïve 
(unformulated) 
GFAP-IL6 6.49 ± 2.03 6.49 0.25 ± 0.11 25 
Demethoxycurcumin 
conjugates (sulfates/ 
glucuronides) 
0  
 
WT 7.55 ± 1.70 7.55 0.65 ± 0.00 65 
0  
 
GFAP-IL6 13.85 ± 2.74 13.85 0.66 ± 0.00 66 
35, Meriva® 
 
GFAP-IL6 42.45 ± 3.67 42.45 0.39 ± 0.09 39 
70, Meriva® 
 
GFAP-IL6 58.28 ± 11.10 58.28 0.43 ± 0.10 43 
140, Meriva® 
(1:2 dilution) 
GFAP-IL6 68.87 ± 12.40 137.74 1.62 ± 0.03 162 
140, naïve 
(unformulated) 
GFAP-IL6 162.08 ± 22.02 162.08 1.06 ± 0.06 106 
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Table 13. Area data, obtained from LC/MS analysis, and calculated plasma concentration of bisdemethoxycurcumin in Meriva® fed and naïve curcumin fed mice*. 
 
 
 
*Raw data presented in Appendix B 
**Expected AUC taking into account any dilution of samples  
***Mean concentration calculated in 1mL of 1:1 ultrapure water: acetonitrile. Free curcumin concentrations were deducted from total curcumin concentrations (if 
concentrations > LLOQ) to calculate conjugates   
**** Mean concentration calculated in 10µL of plasma in each sample x100
Bisdemethoxycurcumin Dosage 
(mg/kg.bw/day), 
formulation 
Mouse 
genotype 
Fed 
Mean AUC ±SE Standardised 
AUC** 
Mean 
Concentration ±SE 
(ng/mL in 
sample)*** 
Mean 
Concentration 
(ng/mL in 
plasma)**** 
Free bisdemethoxycurcumin 0 
 
WT 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
0  
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
35, Meriva® 
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
70, Meriva®  
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
140, Meriva® 
(1:2 dilution) 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
140, naïve 
(unformulated) 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
Bisdemethoxycurcumin 
conjugates 
(sulfates/glucuronides) 
0 
 
WT 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
0  
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
35, Meriva® 
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
70, Meriva®  
 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
140, Meriva® 
(1:2 dilution) 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
140, naïve 
(unformulated) 
GFAP-IL6 0.00 ± 0.00 0.00 0.00 ± 0.00 0.00 
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5. Results (Apigenin project) 
5.1 Justification for analysis 
Initial analyses, grouping male and female data together, determined that in a number of 
test parameters, either a main effect of sex, or a sex interaction (diet*sex, genotype*sex) 
was observed. As shown in Table 14, sex was likely to be a compounding factor in at least 
one test measure per behavioural test.  It was therefore decided that males and females 
should be analysed separately to eliminate this effect. 
Table 14. Significance values for sex main effects and sex interactions (p<0.05) for test parameters in 
behavioural analyses. P-values with a superscripted one represent significance for diet*sex interaction, and 
with a superscripted two represent significance for genotype*sex interactions 
Test Test Parameter Sex Main 
Effect 
P-
value 
Sex Interaction 
(Diet*sex1 
Genotype*sex2) 
P-
value 
Physical 
battery 
Weight Yes 0.013 No 0.1301 
0.7192 
Physical 
battery 
Functional motor activity No 0.631 No 0.6171 
0.8522 
Walking beam Total latency No 0.437 Genotype*sex 0.9361 
0.0062 
Walking beam No. of Foot slips No 0.081 No 0.8921 
0.0842 
Accelerod Total latency Yes 0.049 No 0.9281 
0.0942 
Accelerod  % time spent in passive 
rotation 
No 0.074 No 0.8181 
0.6272 
Barnes maze Primary latency Yes 0.033 No 0.0631 
0.099 
Barnes maze Primary path length No 0.087 No 0.1471 
0.3022 
Barnes maze Primary errors No 0.881 No 0.5021 
0.9812 
Barnes maze Total latency No 0.059 No 0.3181 
0.1652 
Barnes maze  Total path length No 0.324 No 0.2171 
0.4282 
Barnes maze Total errors No 0.692 No 0.3181 
0.4802 
Barnes maze Total head entries  No 0.145 Genotype*sex 0.8851 
0.0372 
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5.2 Physical Battery 
5.2.1 Body weight 
The body weights of mice (18-23 months old, n = 24 males, 16 females) were measured prior to 
behavioural testing to determine if apigenin had any effect on this parameter. We hypothesised 
that apigenin may influence body weight by making the mouse chow more or less palatable in 
comparison to control feed, or that apigenin may have a physiological influence on body weight. 
Weights for male mice are presented in Fig 14A. A significant diet and genotype interaction was 
observed for weight of male mice (F (1, 21) = 4.387, p = 0.049), indicating that the effect of 
apigenin is dependent on the genotype of the mice. The diet and genotype interaction showed that 
in control fed males, no significant difference in body weight was detected between GFAP-IL6 
and WT mice (p>0.05). However, in apigenin fed males GFAP-IL6 mice weighed significantly 
less than WT males (p<0.001). This suggests that apigenin is either having a deleterious effect on 
body weight in GFAP-IL6 males, or a beneficial effect in WT males. Similarly, between 
genotypes, the administration of apigenin resulted in a significantly higher body weight for WT 
males, where apigenin fed mice weighed significantly more than control fed mice (p = 0.004). 
Given that in GFAP-IL6 males, apigenin did not have any effect on body weight (p>0.05), this 
result reiterates that apigenin consumption either contributed to weight gain, or reduced weight 
loss in WT males only. 
Neither diet, nor genotype, had any significant effect on the weight of female mice (Fig 14B). 
However, a large effect size was seen for genotype effects (partial Eta squared >0.14 (127), 
indicating that with a higher number of female mice, a significant difference in weight may have 
been observed between WT and GFAP-IL6 mice.  
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Fig 14 (A-B). Body weight of mice (g). Body weight is shown for males (A), and females (B). A ‘x’ symbol above a 
line linking two or more bars is indicative of a significant interaction between two test parameters. The number of 
symbols is reflective of the level of significance. Data is displayed as the mean ± SE for Wild Type control (WT) and 
GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. XXp<0.05, XXXXp<0.0001. 
 
5.2.2 Functional motor activity  
Functional motor activity was assessed during physical battery testing to provide an initial 
assessment of the motor capabilities of the mice (18-23 months old, n = 24 males, 16 females), 
based on genotype and diet. This parameter was assessed by the allocation of a ‘composite score’, 
where individual scores for gait, kyphosis, ledge test and hind limb clasping are summed to give 
an overall indication of motor deficits in the mice. A higher composite score signifies a higher 
level of motor deficit in the mouse. We therefore aimed to determine if there was a significant 
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difference in functional motor activity between GFAP-IL6 and WT mice, if apigenin was able to 
improve motor function, and if the same trends were observed between males and females. 
 For both male and female mice, GFAP-IL6 mice obtained significantly higher composite scores 
than WT mice (p < 0.001, 0.009; Fig 15A and B, respectively), demonstrating that a more 
advanced level of motor deficit exists in GFAP-IL6 mice . Apigenin did not improve functional 
motor activity in either GFAP-IL6 or WT mice (p>0.05). This was the case for both males and 
females. 
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Fig 15 (A-B). Functional motor activity. Functional motor activity is presented as a composite (summed) score for 
gait, kyphosis, ledge test and hind limb clasping measured during physical battery testing for males (A), and females 
(B). A ‘*’ symbol above a line linking two or more bars is indicative of a main effect between two test parameters. 
The number of symbols is reflective of the level of significance. Data is displayed as the mean ± SE for Wild Type 
control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. **p<0.05, ****p<0.0001. 
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5.3 Walking Beam 
The walking beam is a behavioural test which aims to assess the balance and motor coordination 
of the mice. In this test, the mice (18-23 months old, n = 24 males, 16 females) were assessed on 
the amount of time taken to cross the beam (total latency), as well as the number of times their 
hind paws slipped off the beam (foot slips). A higher latency and total number of foot slips 
indicates diminished motor control. Thus, the aim of this experiment was to determine if there was 
a genotype effect on the degree of motor control between GFAP-IL6 and WT mice, if the 
administration of apigenin was able to alleviate any motor deficiency present, and if any difference 
in trends could be detected between male and female mice.  
 
5.3.1 Total latency 
A genotype effect on walking beam total latency was observed for male mice (Fig 16A), where 
GFAP-IL6 mice took significantly longer to cross the beam than WT mice (F (1, 71) = 53.634, p 
< 0.001). The administration of apigenin did not improve motor function in either genotype (P > 
0.05) 
For female mice, a significant interaction of diet and genotype was observed for walking beam 
total latency (F (1, 44) = 5.513, p = 0.023; Fig 16B), indicating that apigenin effects were genotype 
dependent. As such, in WT females, apigenin improved (decreased) total latency times in 
comparison to control fed mice (p = 0.006), however, had no effect on total latency on GFAP-IL6 
mice (p > 0.05). Similarly, between the genotypes, apigenin fed GFAP-IL6 females spent 
significantly more time traversing the beam than apigenin fed WT females (p < 0.001), suggesting 
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that apigenin effects were stronger in WT females. No difference was observed in total latency 
between control fed GFAP-IL6 and WT females (p >0.05). 
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Fig 16 (A-B). Total latency - walking beam. Total latency was measured during the walking beam test, for males 
(A), and females (B). A ‘*’ symbol above a line linking two or more bars is indicative of a main effect between two 
test parameters. An ‘x’ symbol above a line linking two or more bars is indicative of a significant interaction between 
two test parameters. The number of symbols is reflective of the level of significance. Data is displayed as the mean of 
three trials ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched 
chow. **p<0.05, ****p<0.0001. 
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5.3.2 Foot slips 
A significant genotype effect was seen for the number of foot slips made by male mice during the 
walking beam test (F (1, 71) = 85.972, p < 0.001; Fig 17A). In this case, male GFAP-IL6 mice 
made significantly more foot slips while crossing the beam than WT mice. Apigenin did not have 
an effect on the number of foot slips for either GFAP-IL6 or WT male mice (p > 0.05), and 
therefore did not improve motor function in these mice (Fig 17A). 
As with male mice, a significant genotype difference was observed in the number of foot slips 
made by female mice (F (1, 44) = 252.197, p < 0.001; Fig 17B), where GFAP-IL6 females had a 
higher incidence of foot slips when crossing the beam than WT females. Apigenin had no effect 
on the number of foot slips made by female mice (p > 0.05), indicating that apigenin was unable 
to rescue motor deficits in female mice (Fig 17B).  
 
 
 
 67 
 
W T G F A P -IL 6
0
1 0
2 0
3 0
4 0
#
 F
o
o
t 
s
li
p
s
C o n tro l F e d
A p ig e n in  F e d
* * * *
W T G F A P -IL 6
0
1 0
2 0
3 0
4 0
#
 F
o
o
t 
s
li
p
s
C o n tro l F e d
A p ig e n in  F e d
* * * *
A
B
T o ta l n u m b e r  o f fo o t s lip s  -   M a le s
T o ta l n u m b e r  o f fo o t s lip s  -   F e m a le s
 
Fig 17 (A-B). Total number of foot slips – walking beam. The total number of foot slips made while traversing the 
walking beam is displayed for males (A), and females (B). A ‘*’ symbol above a line linking two or more bars is 
indicative of a main effect between two test parameters. The number of symbols is reflective of the level of 
significance. Data is displayed as the mean of three trials ± SE for Wild Type control (WT) and GFAP-IL6 transgenic 
mice on control chow, or apigenin enriched chow. **p<0.05, ****p<0.0001. 
 
 
5.4 Accelerod 
The accelerod test aims to assess the balance and motor coordination of the mice. For this test, the mice 
(18-23 months old, n = 24 males, 16 females) are placed on a rotating rod, which increases in acceleration 
from 0-40ppm over a period of 300 seconds. Motor coordination and balance are assessed by recording 
the total length of time the mice are able to remain on the accelerod (total latency), and the proportion of 
the test time the mice spend in passive rotation i.e. holding on to the rod with their paws without moving 
 68 
 
them (% time spent in passive rotation). The time spent in passive rotation was analysed in addition to 
total latency, as it may give additional information as to the level of fatigue, motivation and strength of 
the mice. Mice who are able to stay on the accelerod longer, and spend less time in passive rotation are 
deemed to have higher motor function than mice who have shorter latencies and who spend a higher 
proportion of the test in passive rotation. 
By performing the accelerod test, we aimed to determine if there was any difference in balance and motor 
coordination between GFAP-IL6 and WT mice, if the long-term consumption of apigenin was able to 
improve any motor deficits seen, and if there were any differences in these factors which were able to be 
detected between the sexes. 
 
5.4.1 Total latency 
No significant diet or genotype effect on accelerod total latency was observed for male mice (Fig 18A). 
Therefore, motor function was deemed to be similar between genotypes during this test, and apigenin 
did not appear to improve motor skills for either genotype. 
However, for female mice, a significant diet and genotype interaction was observed (F (1, 44) = 9.819, 
p = 0.003; Fig 18B). In apigenin fed females, GFAP-IL6 mice performed significantly worse than WT 
mice (p < 0.001), suggesting that apigenin was unable to rescue motor deficits in GFAP-IL6 mice. In 
fact, within GFAP-IL6 females, apigenin fed mice had significantly shorter latency times than control 
fed mice (p = 0.016), indicating that apigenin had a deleterious effect on the motor function of GFAP-
IL6 mice.  
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Fig 18 (A-B). Total latency – accelerod. Total latency in accelerod is presented for males (A), and females (B). An 
‘x’ symbol above a line linking two or more bars is indicative of a significant interaction between two test parameters. 
The number of symbols is reflective of the level of significance. Data is expressed as the mean of three trials ± SE 
for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. **p<0.05, 
****p<0.0001. 
 
5.4.2 Time spent in passive rotation (% total time)  
No significant effect of genotype or diet was seen to affect the percentage of total time the mice 
spent in passive rotation for either males or females (Fig 19, A and B, respectively). This indicates 
that the motor activity of GFAP-IL6 and WT mice were similar in this test, and that apigenin is 
not able to improve the motor function in either genotype, in both males and females.  
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Fig 19 (A-B). % Time spent in passive rotation. The percentage time spent in passive rotation is presented for males 
(A), and females (B). Data is expressed as the mean of three trials ± SE for Wild Type control (WT) and GFAP-IL6 
transgenic mice on control chow, or apigenin enriched chow. **p<0.05 
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5.5 Barnes maze 
The Barnes maze aims to test spatial recognition, learning and memory. The aim of this test was 
to train the mice (18-23 months old, n = 24 males, 16 females) to learn the location of an ‘escape 
hole’, in amongst 19 other ‘fake holes’, and to then remember this location after a 72-hour rest 
period. 
Primary measures (primary latency, primary path length, and primary errors), total measures (total 
latency, total path length and total errors), and total head entries were recorded during both 
acquisition trials (to indicate learning over two days in six trials) and the probe trial (to assess 
memory). Memory assessment also included observing the total time the mice spent in each of the 
four quadrants during the probe trial. While these measures are suitable to determine performance 
difference for each test parameter based on genotype and diet, it is also important to ascertain 
whether mice from each group are able to learn over time (over six acquisition trials. To determine 
overall learning, a repeated measures ANOVA was used to analyse differences in each test 
parameter between trials. In this case, analysis split by sex was unable to be completed due to low 
numbers of females, so male and female data were grouped together to determine overall learning 
(groups were divided by genotype and diet).  
As with general health and motor skills tests, the aim of conducting the Barnes maze test was to 
determine if there was any difference in cognition between GFAP-IL6 and WT mice, if apigenin 
was able to improve cognition in either genotype, and if patterns of cognition were different 
between males and females. 
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5.5.1 Primary latency (acquisition trials) 
A significant diet and genotype interaction was observed for primary latency in male mice (F (1, 
20) = 22.462, p < 0.001; Fig 20A). For male control fed males, primary latency was significantly 
higher for GFAP-IL6 mice than WT mice (p < 0.001). However, in apigenin fed males, primary 
latency did not differ between GFAP-IL6 and WT mice. This result demonstrates that apigenin 
was able to return GFAP-IL6 primary latency to that which is seen in WT – thus, improving 
learning in the GFAP-IL6 males.  
In female mice, a significant genotype effect was observed (F (1, 12) = 3.903, p = 0.005; Fig 
20B), where primary latency was significantly higher in GFAP-IL6 females than in WT females. 
Nevertheless, there was no significant difference between apigenin fed and control fed females, 
indicating that apigenin did not improve learning in either genotype. 
Overall learning did not improve over the six acquisition trials for GFAP-IL6 mice. This was the 
case for both apigenin fed and control fed animals. Similarly, WT mice learning did not improve 
over the acquisition trials, for both apigenin fed and control fed animals.   
 
5.5.2 Primary latency (probe trial) 
No significant difference in primary latency was achieved between GFAP-IL6 and WT mice 
during the probe trial. Additionally, apigenin did not improve primary latency in the probe trial for 
either genotype, and therefore did not improve learning. This was the case for both males and 
females (Fig 20, C and D, respectively). 
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Fig 20 (A-D). Primary Latency – Barnes maze. Primary latency measured during Barnes maze testing is presented 
for males and females for acquisition and probe trials. Graphs A and B (males and females, respectively) represent 
Barnes maze primary latency (m) in six trials over two days (ACQ 1= First day of acquisition trials, ACQ 2 = Second 
day of acquisition trials). The numbers in brackets indicate the trial number on that particular day. Graphs C and D 
(males and females, respectively) represent Barnes maze primary latency for the probe trial. The data is expressed as 
mean ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. 
**p<0.05 
 
5.5.3 Primary path length (acquisition trial) 
A significant diet and genotype interaction was observed for primary path length in male mice 
(F(1,20) = 2.118, p = 0.003; Fig 21A). The interaction showed that for apigenin fed males, no 
significant difference in primary path length was indicated, whereas in control fed males, GFAP-
IL6 mice had a higher primary  path length than WT mice (p = 0.001). This demonstrates that 
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apigenin improved primary  path length in GFAP-IL6 mice to WT levels, and therefore, that its 
long-term consumption was able to improve learning in GFAP-IL6 mice. This is reiterated by a 
significantly lower primary path length in apigenin fed GFAP-IL6 males , in comparison to control 
fed GFAP-IL6 males (p = 0.008). Apigenin did not improve primary path length in WT males.  
Unlike in male mice, no significant diet or genotype effect was identified for primary path length 
in females (Fig 21B). Thus, we see that our model was unable to be validated for female mice in 
primary path length, and furthermore, apigenin was unable to improve learning. 
Overall learning in GFAP-IL6 mice did not improve over the acquisition trials, for both apigenin 
and control fed mice. However, a large effect size was observed for control fed GFAP-IL6 (Partial 
Eta squared > 0.14 (127)), which suggests that with a larger sample size, a learning trend may 
have been seen. As with GFAP-IL6 mice, learning did not improve over the trials for either 
apigenin fed, or control fed, WT mice. 
 
5.5.4 Primary path length (probe trial) 
During the probe trial, there was no difference in primary path length between apigenin and control 
fed mice, nor between genotypes. This was the case for both male and female mice (Fig 21, C and 
D, respectively). 
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Fig 21 (A-D). Primary path length – Barnes maze. Primary path length measured during Barnes maze testing is 
presented for males and females for acquisition and probe trials. Graphs A and B (males and females, respectively) 
represent Barnes maze primary path length (m) in six trials over two days (ACQ 1= First day of acquisition trials, 
ACQ 2 = Second day of acquisition trials). The numbers in brackets indicate the trial number on that particular day. 
Graphs C and D (males and females, respectively) represent Barnes maze primary path length for the probe trial. 
The data is expressed as mean ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or 
apigenin enriched chow. **p<0.05 
 
 
5.5.5 Primary errors (acquisition trials) 
A significant interaction of diet and genotype was observed for the number of primary errors made 
during the acquisition trials for male mice (F (1, 20) = 11.340, p = <0.003, Fig 22A). Within this 
interaction, no significant difference was detected between GFAP-IL6 and WT apigenin fed males. 
However, in control fed males, GFAP-IL6 mice made significantly more errors than WT mice (p 
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= 0.003). Therefore, apigenin was able to improve learning in GFAP-IL6 by reducing the amount 
of errors made, making the number of primary errors made comparable to WT mice.  
While in GFAP-IL6 males, apigenin resulted in a decreased number of errors made, compared 
with control fed mice (p = 0.029), apigenin fed WT males made significantly more errors than 
control fed WT males. This suggests that apigenin improved learning in GFAP-IL6 mice, while 
reducing learning in WT mice.  
Although a significant diet and genotype interaction was seen for female mice (F (1, 12) = 5.255, 
p = 0.041; Fig 22B), no significant effects could be detected in the subsequent pairwise comparison 
analysis. 
Overall learning for apigenin fed and control fed GFAP-IL6 mice did not improve over the 
acquisition trials. Likewise, overall learning did not improve over the acquisition trials for apigenin 
fed and control fed WT mice. 
 
5.5.6 Primary errors (probe trial) 
The number of primary errors made in the probe trial did not differ significantly between genotypes 
or diets, for either males, or females (Fig 22, C and D, respectively). 
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Fig 22 (A-D). Primary Errors – Barnes maze. Primary errors measured during Barnes maze testing is presented for 
males and females for acquisition and probe trials. Graphs A and B (males and females, respectively) represent Barnes 
maze # of primary errors in six trials over two days (ACQ 1= First day of acquisition trials, ACQ 2 = Second day of 
acquisition trials). The numbers in brackets indicate the trial number on that particular day. Graphs C and D (males 
and females, respectively) represent Barnes maze primary errors for the probe trial. The data is expressed as mean ± 
SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. **p<0.05 
 
 
5.5.7 Total latency (acquisition trials) 
A significant diet and genotype interaction for total latency could be seen for male mice during the 
acquisition trials (F (1, 20) = 21.417, p < 0.0001, Fig 23A). The interaction showed that for 
apigenin fed males, total latency did not differ between GFAP-IL6 and WT mice. On the other 
hand, for control fed males, GFAP-IL6 mice had a significantly higher total latency than WT mice 
(p < 0.001), demonstrating that apigenin was able to improve (decrease) total latency, and thus 
learning, in GFAP-IL6 mice. 
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Within genotypes, apigenin was seen to improve total latency in GFAP-IL6 mice (p = 0.001), 
however, in WT mice, apigenin lead to a longer total latency, compared with control fed mice (p 
= 0.011). This demonstrated that apigenin had a beneficial effect in GFAP-IL6, and a detrimental 
effect on WT mice. 
In female mice, a genotype effect was observed, where total latency was significantly lower for 
WT mice, than for GFAP-IL6 mice (F (1, 12) = 3.269, p=0.002, Fig 23B). Apigenin did not appear 
to have any significant effect on total latency for females.  
Overall learning did not improve in either genotype, regardless of diet. However, for GFAP-IL6 
control fed, WT apigenin fed, and WT control fed mice, a large effect size was present (Partial 
Eta Squared > 0.14 (127)). Thus, with a larger sample size, improved learning may have been 
observed in this test parameter. 
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Fig 23 (A-B). Total latency – Barnes maze. Total latency measured during Barnes maze testing is presented for 
males and females for acquisition trials only. Graphs A and B (males and females, respectively) represent Barnes 
maze total latency (m) in six trials over two days (ACQ 1= First day of acquisition trials, ACQ 2 = Second day of 
acquisition trials). The numbers in brackets indicate the trial number on that particular day. The data is expressed as 
mean ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. 
**p<0.05 
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5.5.8 Total path length (acquisition trial) 
A significant diet and genotype effect was identified for male mice for total path length (F (1, 20) 
= 4.561, p = 0.045, Fig 24A). The interaction shows that for apigenin fed males, there was no 
significant difference in total path length between GFAP-IL6 mice and WT mice, however, in 
control fed mice, GFAP-IL6 mice had a significantly longer path length than WT mice (p = 0.025), 
signifying that apigenin was able to improve total latency in GFAP-IL6 mice to be similar to that 
of WT mice. Within genotypes, apigenin fed and control fed GFAP-IL6 did not differ in total path 
length, whereas apigenin had a detrimental effect on path length for WT mice, with apigenin fed 
mice having a higher total path length than control fed mice (p = 0.049). 
For female mice, no significant diet or genotype effect was observed for total path length (Fig 
24B).  
Overall learning did not improve over the acquisition trials for apigenin fed GFAP-IL6 mice, 
however a large effect size was seen (Partial Eta Squared > 0.14 (127)), indicating that with a 
higher number of mice, a learning trend may have been seen. On the other hand, an overall learning 
trend was seen for control fed GFAP-IL6 mice (F (5, 45) = 2.555, p = 0.041), although pairwise 
comparisons did not indicate a significant difference between individual trials.  Both apigenin fed 
and control fed WT mice showed no improvement in learning over the acquisition trials. 
 
5.5.9 Total path length (probe trial) 
During the probe trial, total path length was found to be significantly lower in GFAP-IL6 males, 
than in WT males (F (1, 20) = 4.646, p = 0.043; Fig 24C). An effect of diet on total path length 
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was not seen for male mice. In female mice, neither diet, nor genotype had an effect on total path 
length values (Fig 24D). 
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Fig 24 (A-D). Total path length – Barnes maze.  Total path length, measured during Barnes maze testing is presented 
for males and females for acquisition and probe trials. Graphs A and B (males and females, respectively) represent 
Barnes maze total path length (m) in six trials over two days (ACQ 1= First day of acquisition trials, ACQ 2 = Second 
day of acquisition trials). The numbers in brackets indicate the trial number on that particular day. Graphs C and D 
(males and females, respectively) represent Barnes maze total path length for the probe trial. The data is expressed as 
mean ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, or apigenin enriched chow. 
**p<0.05 
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5.5.10 Total errors (acquisition trials) 
For male mice, a significant diet and genotype interaction for total errors was determined (F 
(1, 20) = 10.466, p = 0.004; Fig 25A). This interaction showed that in apigenin fed males, no 
significant difference was seen in the number of total errors made between GFAP-IL6 and 
WT mice. In control fed males, however, GFAP-IL6 made significantly more total errors than 
WT mice (p = 0.001). This demonstrates the beneficial effect of apigenin on the total number 
of errors made for GFAP-IL6 mice, resulting in similar number of total errors between GFAP-
IL6 and WT mice.   
In WT males, apigenin fed mice made significantly more errors than control fed mice (p = 
0.006). In this instance, apigenin had a deleterious effect on the total number of errors made 
in WT mice. In GFAP-IL6 mice, however, no significant difference in the total number of 
errors made was observed between apigenin fed and control fed mice. 
The total number of errors made by females was significantly higher in GFAP-IL6 mice, than 
in WT mice (F (1, 12) = 4.841, p = 0.048; Fig 25B). Diet did not have any significant effect 
on the total errors made by female mice.  
Overall learning over the acquisition trials was not observed in GFAP-IL6 mice for either 
apigenin fed or control fed mice. However, for both these groups, a large effect size was 
identified (Partial Eta squared > 0.14 (127)). Similarly, in WT mice, no significant overall 
learning was observed for either control and apigenin fed animals.  
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5.5.11 Total errors (probe trial) 
Total errors made during the probe trial were significantly lower for GFAP-IL6 males, than 
for WT males (F (1, 20) = 4.699, p = 0.042; Fig 25C). This was also the case for female mice 
(F (1, 12) = 6.015, p = 0.030; Fig 25D). No significant effect of diet was found on the number 
of total errors for either sex. 
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Fig 25 (A-D). # Total errors – Barnes maze. # Total errors, measured during Barnes maze testing is presented 
for males and females for acquisition and probe trials. Graphs A and B (males and females, respectively) 
represent Barnes maze # total errors in six trials over two days (ACQ 1= First day of acquisition trials, ACQ 2 
= Second day of acquisition trials). The numbers in brackets indicate the trial number on that particular day. 
Graphs C and D (males and females, respectively) represent Barnes maze # total errors for the probe trial. The 
data is expressed as mean ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control chow, 
or apigenin enriched chow. **p<0.05 
 
5.5.12 Total head entries into escape hole (acquisition trial) 
The total number of head entries made by male mice into the escape hole was seen to not be 
affected by diet or genotype during acquisition trials (Fig 26A).  
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In female mice, a genotype effect was observed, where WT mice made significantly less head 
entries into the escape hole than the GFAP-IL6 mice (F (1, 20) = 4.372, p = 0.009, Fig 26B), 
validating the current model for this test parameter. No diet effect was observed between trials 
for female mice, indicating that apigenin was unable to improve memory in this task.   
For overall learning trends, neither apigenin fed nor control fed GFAP-IL6 mice demonstrated 
any improvement in learning over the acquisition trials, however, a large effect size was seen 
for apigenin fed GFAP-IL6 mice, which suggests that a learning trend may have been seen 
with a higher number of mice included in the study. 
An improvement in overall learning was seen for control fed WT mice (F (5, 65 = 1.099), p 
= 0.001), however no differences were detected in pairwise comparisons. No improvement 
in learning was seen for apigenin fed WT mice. 
 
5.5.13 Total head entries to escape hole (probe trial) 
For male mice in the probe trial, a significant genotype and diet interaction existed for the 
total number of head entries made into the escape hole (F (1, 20) = 6.357, p = 0.020, Fig 
26C). This interaction showed that for apigenin fed males, there was no significant difference 
in the total number of head entries made during the probe trial. In contrast, in control fed 
males, GFAP-IL6 mice made significantly less head entries in the escape hole for this trial (p 
= 0.002). This signifies the positive effect apigenin had in improving the ability of GFAP-
IL6 to identify the escape hole after a rest period of 72 hours, and thus, demonstrates an 
improvement in memory comparable to WT levels. Neither diet, nor genotype effects were 
observed for female mice during the probe trial (Fig 26D).  
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Fig 26 (A-D). # Head entries into escape hole (EH). # Head entries into EH, measured during Barnes maze 
testing is presented for males and females for acquisition and probe trials. Graphs A and B (males and females, 
respectively) represent Barnes maze # Head entries into EH in six trials over two days (ACQ 1= First day of 
acquisition trials, ACQ 2 = Second day of acquisition trials). The numbers in brackets indicate the trial number 
on that particular day. Graphs C and D (males and females, respectively) represent Barnes maze # Head entries 
into EH for the probe trial. The data is expressed as mean ± SE for Wild Type control (WT) and GFAP-IL6 
transgenic mice on control chow, or apigenin enriched chow. **p<0.05 
 
 
5.5.14 Total time spent in quadrants (Probe trial)  
The total time the mice spent in each test quadrant during the trial was measured as an 
additional parameter to indicate learning in the probe trial. The circular platform of the Barnes 
maze was divided into a number of zones, including four quadrants (Q1, Q2, Q3 and Q4). 
Quadrant 3 (Q3) contained the escape hole, and quadrant 1 (Q1) was the quadrant opposite 
the escape hole. We hypothesised that if mice remembered the location of the escape hole 
(which is removed during the probe trial), they would spend significantly more time in Q3 
than the other quadrants. This would demonstrate how ‘insistent’ the mice were of the location 
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of the previously present escape hole. The aim of analysing the total time spent in the 
quadrants was to determine if there was any difference in memory between GFAP-IL6 and 
WT mice, and if apigenin was able to improve memory in either genotype. Due to the low 
number of female mice, male and female data was grouped for this analysis. 
For GFAP-IL6 mice, the amount of time spent in each quadrant was significantly different (F 
(3, 42) = 5.243, p = 0.004; Fig 27A). Pairwise comparisons showed that GFAP-IL6 mice 
spent significantly longer in Q3 (escape hole quadrant) than in Q1 (opposite quadrant) (p = 
0.005), and spent significantly more time in Q2 than Q1 (p = 0.001). GFAP-IL6 spent the 
least amount of time in Q1, and the most amount of time in Q3. No significant difference was 
observed in pairwise comparisons between time spent in Q2, Q3 and Q4. Apigenin did not 
increase the amount of time spent in Q3 (escape hole quadrant) or decrease the amount of 
time spent in the other quadrants, which suggests that apigenin was unable to improve 
memory in GFAP-IL6 mice. 
Similarly, the amount of time WT mice spent on the Barnes maze differed significantly 
between quadrants (F (2, 66) = 15.624, p < 0.001; Fig 27B). Pairwise comparisons showed 
that the amount of time spent in Q3 (escape hole quadrant) was significantly higher than in 
Q1 (p = 0.002), Q2 (p = 0.001) and Q4 (p < 0.001). Apigenin did not increase the amount of 
time WT mice spent in the escape hole quadrant, or decrease the amount of time spent in other 
quadrants. 
These results suggest that GFAP-IL6 mice did not remember the location of the escape hole 
as effectively as WT mice. Furthermore, apigenin was not seen to affect quadrant time in 
either genotype, and therefore was not effective in improving memory. 
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Fig 27 (A-B). Total time spent in each quadrant – Barnes maze. The total time spent in each quadrant, 
measured during Barnes maze testing is presented for GFAP-IL6 mice (A) and WT mice (B) for the probe trial. 
The data is expressed as mean ± SE for Wild Type control (WT) and GFAP-IL6 transgenic mice on control 
chow, or apigenin enriched chow. **p<0.05 
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6. Discussion 
6.1 Discussion – Curcumin Project 
6.1.1 Curcumin concentration in mouse chow pellets 
Determining curcumin concentration in the mouse chow pellets used for this study intended 
to ascertain whether the mice would be able to consume the experimental dosage for each 
group. Our results demonstrated that for the majority of dosage groups, extraction efficiency 
was around 90%, indicating that the mice were able to achieve consumption of the correct 
dosage. The only exception to this was the 140 mg/kg.bw/day Meriva® group, where a 78% 
extraction efficiency was achieved. A lower than expected curcumin concentration is likely 
to have flow-on effects for plasma curcuminoid concentrations, and even in subsequent 
testing e.g. behaviour or histology. Further investigation into the reasons behind this reduction 
should be initiated, and whether this trend is consistent between different batches of feed. As 
this analysis was completed using spectrophotometry, which cannot distinguish between each 
curcuminoid, future analysis should be completed using LC-MS/MS, with the aim of 
quantifying each curcuminoid separately. Studies analysing mouse chow often look to 
determine the presence of degradation e.g. (128, 129). To this author’s knowledge, no long-
term feeding study involving curcumin has quantified curcumin concentration in chow pellets. 
However, we would suggest that this is a crucial step, particularly in the absence of oral 
gavage, to ensure accuracy of experiments and any conclusions drawn from the study. 
Techniques used for extraction can affect the overall outcomes of the study, and therefore, it 
will be useful to develop the current method to optimise extraction efficiency for more 
accurate results in future studies.  
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6.1.2 Assessment of pilot study methodology 
6.1.2.1 Biological matrices and their complexities in LC-MS/MS analysis 
Bioanalysis in the pharmaceutical industry is increasingly utilizing LC-MS/MS for qualitative 
and quantitative analysis, largely due to the speed, sensitivity and specificity of the method, 
which allows for fast turnover of samples, with high quality data (96, 130). However, the 
reliability of this analytical technique has come under considerable scrutiny, due to a number 
of limitations encountered, particularly during assay development. For many bioanalytical 
analyses, analytes will often need to be detected in trace amounts within complex, and often 
inconstant matrices, which can cause numerous analytical problems, such as matrix effects, 
sensitivity issues, and reduced accuracy and precision (93).  
In the current pilot study, we aimed to develop a valid LC-MS/MS method that would be able 
to detect curcuminoids in curcumin-fed mouse plasma. Our results illustrated the limitations 
of working with a complex biological matrix, such as plasma. In the first instance, matrix 
suppression was observed for all three curcuminoids, with measured concentrations of spiked 
plasma samples deviating from solvent standards at a range of 38 to 71% below expected 
concentrations.  
One of the most problematic aspects of LC-MS/MS method development and analysis, and 
one that has received extensive attention in the literature, is the “matrix effect”. Matrix effects 
are caused by co-eluting matrix components that impact the degree of ionisation at the source, 
to result in either enhancement of the analyte response (matrix enhancement) or reduction in 
analyte response (matrix suppression) (131). Plasma samples are particularly prone to matrix 
effects, such as matrix suppression, due to their high phospholipid content (132). 
Phospholipids are believed to be the main cause of matrix effects in LC-MS/MS bioanalysis 
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(132, 133). Matrix effects can also be attributed to other sources, including proteins, drugs, 
metabolites, salts, or contamination (134). 
Although a prevalent occurrence in LC-MS/MS analysis, a large proportion of studies do not 
address matrix effects within their studies. However, this phenomenon is gaining increased 
coverage in the literature, particularly as the extensive effects of matrix effects are 
acknowledged or more thoroughly understood. With this increasing understanding, studies 
are increasingly, not only discussing this issue, but also attempting to address it. Many 
strategies attempting to deal with matrix effects relate to sample clean-up prior to analysis. A 
range of techniques such as protein precipitation (PPT), liquid-liquid extraction (LLE), and 
solid-phase extraction (SPE) have been explored, and assessed for their suitability to reduce 
the impacts of matrix effects in LC-MS/MS analysis. For example, Chambers et al 2007 (135) 
assessed a number of sample preparation techniques in their ability to reduce the matrix effect. 
They determined that using LLE as a sample clean-up technique resulted in clearer extracts, 
but impacted the recovery of polar analytes. Similarly, SPE also resulted in cleaner extracts 
and reduced matrix effects, compared with LLE. PPT was found to be the least effective 
technique in reducing matrix effects. In another study (136), sample preparation techniques 
(PPT, LLE and SPE) were compared, along with the ionisation type (electrospray ionisation 
(ESI) vs atmospheric-pressure chemical ionisation (APCI)), and the biological fluid being 
analysed (e.g. oral fluid vs plasma). It was found that the largest matrix effects were observed 
with samples that underwent PPT sample preparation and ESI. 
While studies like the above may provide a basis for addressing matrix effects in other 
experiments, the results should be considered in context. This is because, given the vast range 
and variability of biological matrices and of analytes, any interferences that occur during 
analysis are often difficult to predict and reproduce (134). Thus, one of the most problematic 
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considerations in attempting to deal with matrix effects is that there is no collective way to 
address them (137). 
For this study, we attempted two methods to mitigate matrix effects; the addition of plasma 
to standard solutions, and protein precipitation (PPT). The addition of plasma to standards 
attempted to account for differences in signal output between pure solvent standard solutions, 
and test samples. As AUC was higher in our pure solvent standards, adding the same volume 
of plasma to standard solutions, as what was included in the test samples, gives a clearer 
indication of the AUC we can expect in the face of the matrix suppression which is occurring 
at that particular concentration. This can be more easily compared with concentrations present 
in test samples. This has also been a technique used in other studies that have measured 
curcuminoid concentration in plasma e.g. (63, 87). Given that matrix suppression is occurring, 
it is likely that the concentrations calculated for this study are lower than the actual 
concentrations in samples. Thus, in order to address matrix effects in future studies, other 
avenues must be explored. 
During assay development, we also attempted a sample clean-up through PPT, where the 
addition of 90% formic acid precipitated proteins out of solution, so that they were able to be 
separated from the extraction liquid. PPT is a common sample preparation technique, given 
it is simple, fast, and cost-effective (139). However, its success in reducing or eliminating 
matrix effects is somewhat limited as many of the other matrix components contributing to 
the matrix effect, such as phospholipids are still retained (135). 
Numerous LC-MS/MS studies dealing with plasma samples have used SPE as a sample 
preparation technique, which, in comparison to PPT, results in far cleaner samples (139). 
Furthermore, SPE may also have benefits over LLE, where larger sample volumes are 
required, and the potential for cross-contamination is prevalent e.g. from evaporation. SPE 
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(Fig 28) uses a cartridge type device which contains solid particle packing material to separate 
components of a liquid sample (140). It is clear that any alterations to our technique in terms 
of sample preparation will need to balance time, simplicity and cost-effectiveness with an 
improvement in accuracy and sensitivity of the method. 
 
 
Fig 28. SPE method schematic 
 
Additionally, matrix effects may be mitigated by the use of a stable isotopically labelled (SIL) 
analogue of the target analyte (141) as an internal standard (IS). Due to the similarity in 
structure between the analyte and the SIL, one would expect that any matrix effects would be 
consistent between the two compounds (142). Therefore, while the absolute response of the 
analyte would be affected, using a ratio of analyte to IS peak would, in theory, balance out 
any matrix effects, resulting in a method that is more likely to be precise, accurate and rugged 
(142). 
 92 
 
6.1.2.2 Method validation 
To determine the suitability of our developed method, in addition to assessing the matrix 
effect, the linearity of the detector response, and the limits of detection and quantification 
were also evaluated. 
For linearity data, plasma was spiked with curcuminoids of increasing concentration to assess 
their effect in an appropriate biological matrix. Ideally, the detector response should be linear 
over the predicted concentration range of the analyte/s in the sample, have a minimum of 5 
calibration points, and a correlation coefficient ≥0.999 (143). In the current study, we used 8 
calibration points (including a blank), and for all three curcuminoids, we achieved a 
correlation coefficient greater than 0.999, indicating that over the concentration range chosen, 
the detector response can be considered linear. 
LLOD and LLOQ are important considerations in method validation, and aim to determine at 
which concentration an analyte response can be distinguished from background noise (LLOD) 
(144), and the lowest concentration which can be reliably quantified with precision and 
accuracy (LLOQ) (137). LLOD and LLOQ for curcuminoids are highly variable in the 
literature and largely dependent on the method of analysis. For example, in a study where 
curcuminoids were quantified in plasma using HPLC with UV detection (145), LLOD for 
curcumin, demethoxycurcumin and bisdemethoxycurcumin was determined to be 16.9 nM 
(6.23ng/mL), 15.6 nM (5.28ng/mL) and 18 nM (5.55ng/mL), respectively. LLOQ was 33.8 
nM (12.45ng/mL), 31.1 nM (10.52ng/mL) and 32 nM (9.87ng/mL). In contrast, in another 
study (146), where curcuminoids were quantified in plasma using UHPLC/ESI-QTOF-
MS/MS, LLOD for curcumin, demethoxycurcumin and bisdemethoxycurcumin was 0.153, 
0.015 and 0.052 ng/mL, and LLOQ was 0.46, 0.05, and 0.6 ng/mL, respectively. Similarly, 
in another LC-MS/MS study (147) where only LLOD was reported, values for curcumin, 
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demethoxycurcumin and bisdemethoxycurcumin were 1, 1 and 0.5 ng/mL, respectively. 
Although a large variability exists in the literature, LLOD and LLOQ results from this study, 
nonetheless, lie within the range of the values in similar studies of the same analytical method.  
There are also other methods for validation. The Food and Drug Administration (FDA 
outlines a number of key validation parameters that should be measured during method 
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6.1.2.3 Improving sensitivity of the method 
Given the low concentrations of curcuminoids that were measured within this study, 
improving upon sensitivity of the method is essential to ensure we are, firstly, detecting 
curcuminoids in all samples in which it is present; and secondly, to ensure we have detected 
the correct concentrations within the samples. As discussed in the previous sections, 
addressing matrix effects will inevitably lead to an improvement in sensitivity, and should be 
highly considered for future experimental work. Additionally, a further two techniques may 
be helpful in improving sensitivity of the current method; concentrating the sample, and using 
a large volume injection (LVI). 
The final volume for samples in this study were 1mL in 1:1 ultrapure water: acetonitrile. 
However, only 10µL of plasma was contained within this volume. Further investigation 
should be conducted to determine the extent to which the samples can be concentrated (either 
by obtaining more plasma, or by reducing the final volume) without affecting the 
chromatography. Highly concentrated samples can result in diminished mass accuracy, and 
possibly incorrect conclusions (149). 
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Another common method to improve sensitivity of LC-MS/MS is to inject a larger volume of 
the sample (LVI). However, using LVI as a method on its own is likely to compound 
analytical issues including matrix suppression, peak broadening, and reduced peak separation 
(96). Therefore, if this technique is to be used to improve sensitivity, it should be used in 
conjunction with off-line sample preparation such as SPE. In the current study, a total volume 
of 10µL is injected per sample. Further testing will be required to test increasing volume 
conjointly with sample clean-up, to balance an increase in sensitivity with a loss of 
chromatography.  
 
6.1.2.4 Contamination potential 
For demethoxycurcumin, detectable, but not quantifiable, amounts were detected in both WT 
and GFAP-IL6 mice. Interestingly, in the same samples, curcumin could not be detected. In 
both Meriva® and naïve curcumin supplemented feeds used in this study, curcumin is the 
most predominant curcuminoid, and as such, one would expect that if  demethoxycurcumin 
is able to detected, curcumin should also be able to be detected, and in higher amounts. While 
it is difficult to draw conclusions from the plasma measurements of one mouse, it may signify 
an issue that needs to be addressed for future testing. 
For example, it may be possible that this is the result of contamination somewhere in the 
sample preparation stage, such as spills or aerosols (150). The contamination source may be 
caused by system contamination, such as dissolved gases (151). If contamination is occurring, 
this may be exacerbated by the gradient elution used in this method, given that contaminants 
may bind to and accumulate on the column stationary phase, and then elute once gradient 
conditions have changed (152). If contamination is occurring, it is often difficult to locate the 
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source. However, potential sources should be identified during assay development, and steps 
taken to reduce the likelihood of this occurring. 
 
6.1.3 Curcuminoids in mouse plasma 
Preliminary results from this study indicate that we were able to detect low quantities (ng/mL) 
of curcumin and demethoxycurcumin (free, conjugated, or both) in particular dosage groups. 
However, we were not able to detect bisdemethoxycurcumin in any dosage group.  
Interestingly, despite a number of pharmacokinetic studies suggesting increased 
bioavailability of phytosome encapsulated curcumin in comparison to unformulated curcumin 
(153-155), our study found that free curcumin was able to be detected only in the plasma of 
the mouse fed naïve curcumin. However, for conjugated metabolites, both 70 and 140 
mg/kg.bw/day Meriva® groups had higher levels than the naïve curcumin group.  
It should be noted that comparisons between this study, and many others should be treated 
with caution. A large proportion of studies measuring curcuminoid concentration in plasma 
aim to develop detection methods using analytical chemistry techniques, or determine 
curcuminoid metabolism in pharmacokinetic studies. Inconsistencies between studies may 
arise from factors such as the analytical technique used (e.g. HPLC vs LC-MS/MS), the assay 
method employed (e.g. sample preparation), the formulation measured, and the method of 
administration (e.g. oral vs intravenous (IV) administration). In comparison to the current 
study, the drug administration is often a single dose, with measurements taken a short time 
after the application of the dose. For example, (92) administered a single 500mg/kg dose of 
curcumin formulated with piperine and could not detect curcumin in the plasma up to 24 
hours. They attributed this finding to the limited sensitivity of their HPLC method, as they 
were able to detect curcumin in other tissues up to several days later.  In another study (156), 
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curcumin was administered orally to mice in a single dose of 1000mg/kg. Curcumin in plasma 
was measured using LC-MS, where it was found that Cmax of curcumin in plasma was 0.353 
µM (130.04 ng/mL), measured up to 24 hours after dosing. Our study involved long-term 
feeding of the mice, over a 30-day period. The mice were given free access to food and water 
during this time, as oral gavage would likely impede any future behavioural experiments due 
to diminished trust between mouse and handler. Therefore, it was not possible to determine 
the length of time between when the mouse consumed the chow last, and the time it was 
culled, making concentration comparisons difficult, particularly due to the use of a single 
mouse per concentration group. Long term feeding studies, such as ours, are scarce, but 
critically important in understanding the long-term effects of curcumin administration, which 
are much more reflective of real-world applications. That being said, there are some long-
term feeding studies where plasma concentrations are able to be compared more accurately. 
For instance, in a study conducted by Kocher et al 2015 (157), mice (3 months’ old, or 18 
months’ old) were fed with either 500 or 2000 mg/kg curcuminoids for a period of 3 weeks. 
They found the mean curcumin concentration in plasma to be around 1800 nM (663.08 
ng/mL) in 18 month old mice fed 2000mg/kg curcumin feed, and around 500 nM in 3 month 
old mice (184.19 ng/mL) fed the same. In comparison, our study, where the 140 
mg/kg.bw/day naïve curcumin feed contained 0.87g/kg of curcumin, determined a curcumin 
concentration of 114ng/mL in plasma.  
Nonetheless, given that we detected higher levels of conjugated levels of curcuminoids in the 
two highest Meriva® dosage groups, in comparison to the naïve curcumin, we can speculate 
that in fact, initial bioavailability of curcuminoids in the Meriva® groups may have been 
higher than in the naïve curcumin group. It may be the case that an initial higher curcuminoid 
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concentration may have undergone rapid metabolism to end up with a higher conjugated 
concentration. 
However, higher bioavailability does not necessarily translate to health benefits. For example, 
Borbon et al 2012 (158) compared survival rates of Npc1−/− mice fed with unformulated 
curcumin (low bioavailability), as well as a phosphatidylcholine curcumin formulation (high 
bioavailability), and found only slight increases in survival. Interestingly, there was no 
significant difference in the survival rates between the different curcumin fed groups. 
This discrepancy between higher bioavailability and health benefits poses the question: Is 
curcumin the only player that should be considered? A growing number of studies have begun 
to consider the idea that curcuminoid metabolites, including conjugated curcuminoids, may 
be just as bioactive, if not more than, the parent compounds themselves. For instance, Begum 
et al 2008 (159) investigated the curcumin metabolite, tetrahydrocurcumin, and its efficacy in 
an AD and neuroinflammation mouse model. They determined that tetrahydrocurcumin was 
effective in reducing neuroinflammation and soluble β-amyloid peptide. In other studies, 
curcumin conjugates have demonstrated efficacy as anti-cancer agents (160-162). 
Additionally, they have been seen to act as a proteasome inhibitor (162), as well as an anti-
microbial agent (160). The major focus of most curcumin related studies, however, is on 
curcumin itself. Other curcuminoids, and metabolites, have limited literature attention. 
However, it is clear that this is an area that requires further investigation. 
Although conjugates are the most common form of curcumin content found in the plasma 
(163), if we consider them in the context of treating neuroinflammation, they are in fact, 
unlikely to be able to cross the BBB (154). However, there is speculation that an immune 
response for neuroinflammation can begin in the periphery (164). Thus, it is quite possible 
that curcuminoids and/or their metabolites may not need to reach the brain in order for them 
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to treat neuroinflammation, but rather, they may be able to treat neuroinflammation in the 
periphery. 
 
6.1.4 Future Direction 
This study represents the first step in determining the potential of Meriva® curcumin in 
treating neuroinflammation. In order to answer this question in its entirety, in the first 
instance, Meriva® curcumin concentration needs to be determined in mouse plasma, which 
has been achieved in this pilot study. However, this is simply the first stage of method 
development. From this point, the method will need to be developed further to address a 
number of issues encountered during assay development and subsequent testing, such as 
matrix effects and sensitivity. Once this has been achieved, it will be necessary to apply the 
new method to brain tissue of mice fed with Meriva® and naive curcumin to determine if 
Meriva® can reach the brain, and if so, how do concentration levels compare with 
unformulated curcumin? Ideally, to relate this back to a mouse model of neuroinflammation, 
brain concentrations should be correlated with behavioural studies to investigate the effect of 
Meriva® curcumin on memory, learning and motor function, as has been done with apigenin 
in the other section of this project. Additionally, histological data can provide additional 
information on inflammatory markers. Assuming promising results from these endeavours, 
this could pave the way for Meriva® curcumin to be tested in human trials. There is a great 
need for further understanding into the mechanisms of how curcumin is able to treat 
neuroinflammation, particularly in regards to the bioactivity of metabolites, including 
conjugates. 
 
 99 
 
6.2 Discussion – Apigenin Project 
6.2.1 Body weight 
The body weight of the mice was measured to determine if the long-term consumption of 
apigenin affected the body weight of the mice, either positively or negatively. We found that 
male and female mice responded differently to apigenin treatment. For male mice, apigenin 
fed WT mice had a larger body weight that control fed WT mice, indicating that apigenin was 
able to either increase body weight, or reduce weight loss in male mice lacking 
neurodegenerative symptoms. This effect was not observed in female mice. The role of IL-6 
in immune response is relatively well understood, however, what is less understood, and 
somewhat controversial, is the possible role IL-6 plays in metabolism and weight control 
(165, 166). Our results are consistent with a study (167), where it was found that GFAP-IL6 
mice were resistant to increases in body weight, following the administration of a high fat diet 
(55% kcal from fat). They also demonstrated that this effect was stronger in males, than in 
females, again, reflecting the results of this study. Although the exact reasons GFAP-IL6 mice 
may be resistant to weight gain are unclear, this may be explained by the smaller number of 
female mice in the present study, or may be due to differences in metabolism (167) and 
original body weights between males and females.  
Given that in this study, we tested older mice (18-23 months of age); these results may have 
implications for certain age-related phenomena. For instance, in both animals and humans, 
muscular atrophy and loss of skeletal mass occurs as a natural part of the ageing process (168). 
This becomes problematic in the elderly, due to an increased propensity for falls which 
account for 6% of critical hospital visits in elderly patients (169), with the possibility of 
serious injury. While the administration of apigenin may not be useful in preventing this age-
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related decline from occurring in those suffering from neurodegenerative disorders, apigenin 
may be able to slow or reverse this decline in other elderly persons.  
While no previous study alludes to the contribution of apigenin reducing age-related weight 
loss, another study (170) found that the administration of other dietary polyphenols from a 
young age, reduced the decline of mitochondrial functions in rat skeletal muscles by 
decreasing oxidative stress – believed to be a fundamental process in reducing skeletal muscle 
impairment. Further research is required to understand the exact reasoning behind why 
GFAP-IL6 are resistant to weight gain, as well as why this effect is seemingly stronger in 
males than female mice.  
 
6.2.2 Apigenin in improving motor function 
 One of the prominent pathologies of many neurodegenerative diseases is a progressive loss 
of motor function. For example, in AD, sufferers may experience diminished postural ability, 
reduced gait speed, and larger step-to-step variability than non-affected adults (171, 172). 
This decline in motor function observed in neurodegenerative disorders is reflected in GFAP-
IL6 mice, where motor skills decline progressively from 6 months of age.  
In the current study, GFAP-IL6 mice performed worse compared with WT in functional motor 
activity, and in both total latency (effect seen for male mice only) and total foot slips made 
during the walking beam test. In the above cases, the administration of apigenin did not 
improve motor function. As with body weight, females experienced a different trend, where 
the administration of apigenin had a deleterious effect on walking beam total latency in 
GFAP-IL6 females, but a beneficial effect in WT females. Similarly, apigenin fed female 
GFAP-IL6 females fared worse than WT females in accelerod total latency. Neither diet, nor 
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genotype, had any effect on the percentage time spent in passive rotation during the accelerod 
test for either sex. 
Functional motor activity has not been assessed in a published GFAP-IL6 mouse study. 
However, the results from this study indicate that our model is validated, given the distinct 
difference observed in composite scores between the genotypes, where GFAP-IL6 mice 
achieved a higher score i.e. a worse performance, compared with WT mice. This demonstrates 
that this is an appropriate model in which to test the effects of therapeutics in treating 
neuroinflammation and neurodegenerative diseases.  
Similarly, the genotype effect seen in the walking beam test parameters indicates that this 
model is validated with this test, also. The walking beam is a sensitive motor test, which can 
be useful in detecting loss of motor skills due to age, lesions or pharmacological interventions 
(173). The walking beam has been used to validate mouse models of neurodegenerative 
disease, such as Huntington’s disease (174), and Parkinson’s disease (175). 
The walking beam tends to be a more sensitive test than the rotarod test (similar to accelerod, 
without acceleration of the rod), highlighting finer motor deficiencies, in comparison to the 
rotarod test, which measures gross motor deficits (176). This may explain why our results 
were able to detect a genotype effect in the walking beam test, but not in the accelerod.  
For some behavioural parameters, however, the exact function or relevance may not be as 
clear-cut. In the current study, this was applicable when assessing the levels of passive 
rotation that occurred during the accelerod test. Some studies have noted the occurrence of 
passive rotation and considered it distinctly from motor function (177, 178). It may be that, 
rather than providing an assessment of motor function, that passive rotation may be 
representative of the level of fatigue, lack of strength or reduced motivation of the mice (178). 
To eliminate this as a confounding factor, it may be useful, in future experiments, to increase 
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the diameter of the rotating rod. Rustay et al 2003 (179) studied the effects of variable sizes 
of rotating rods in reducing the extent of passive rotation, and found that rods with a diameter 
larger than 6.3cm was able to eradicate the occurrence of passive rotation.  
While the in vitro effects of apigenin have been studied extensively, its efficacy in animal 
studies has seen little investigation thus far. However, in one study conducted by Anusha et 
al 2017 (180), the effect of apigenin (chow concentrations of 10 and 20mg/kg) on rotarod 
performance was assessed in Sprague-Dawley rats (3 months of age). The rats were injected 
with rotenone to induce PD-like symptoms. In this study, apigenin improved rotarod 
performance and thus motor functioning of the rats; and was, therefore, considered a potential 
therapeutic treatment for PD. 
The results of the current study may differ from those of Anusha et al 2017 (180) due to the 
age of the animals tested. As is the case in humans with neurodegenerative disease, motor 
skills in GFAP-IL6 mice decline steadily with age/progression of the disease (118), so it is 
quite possible that at some point, the effect of the drug will be outweighed by the severity of 
the disease. Animal studies that test apigenin at different life stages of laboratory animals may 
be useful in assessing if apigenin effects change over time and age of the animals.  
 
6.2.3 Apigenin in improving learning and memory 
Neurodegenerative disorders, such as AD, are characterized by a number of cognitive deficits, 
such as memory impairment (181), and reduced visual spatial cognition (182), which becomes 
increasingly prevalent with the progression of the disease. Similarly, in GFAP-IL6 mice, 
learning and memory impairments increase with transgene dose and age (183).  
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In assessing the cognitive abilities of GFAP-IL6 mice, we aimed to determine, firstly, if any 
genotype differences in learning and memory could be observed between GFAP-IL6 and WT 
mice; and secondly, if apigenin was able to improve learning and memory over time. To do 
this, we employed the use of the Barnes maze test. The Barnes maze is one of the most 
common methods used to assess memory, learning and spatial awareness in laboratory 
animals, where the navigational abilities and any changes in performance are assessed over 
time (184). While inducing less stress on the animals than other cognitive tests such as the 
MWM (184), aversive stimuli such as sound and light used in Barnes maze testing may, in 
fact, be insufficient motivation for the mice to enter the escape hole (185, 186). However, this 
does not necessarily mean the mice do not know the location of the escape hole. Therefore, 
in the current study, we have analysed primary measures e.g. primary latency, in addition to 
total measures e.g. total errors, which will determine how quickly the mice identify the 
location of the escape hole in the first instance. The inclusion of primary measures is more 
likely to reflect changes in spatial learning than total measures (187). 
Barnes maze acquisition trials provide an indication of learning over time. Due to the degrees 
of freedom being too low for analysis of female mice separately, males and females were 
grouped together for analysis to determine any learning trends occurring over the six trials, 
due to diet, genotype, or both. Our results indicated that within most test parameters, no 
significant learning was seen to occur over the six trials. In some cases, such as total path 
length, this may be explained by reduced motivation over the trials. However, in some 
instances, e.g. primary latency, although no significant difference was observed in learning 
over the trials, a large effect size was observed (Partial Eta square ≥0.14 (127), which 
indicates that with a larger study size, significant learning may have been observed. Further 
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testing will need to be conducted to determine if this is the case, or if apigenin simply does 
not improve learning in this mouse model.  
We also aimed to see if any learning trends could be observed within individual test 
parameters and if this was influenced by diet and/or genotype. As in previous results, different 
trends were observed for male and female mice. For example, in male GFAP-IL6 mice, 
apigenin was able to improve primary latency, primary path length, primary errors, total 
latency, total path length and total head entries to the same levels as those seen in WT males. 
In female mice, however, apigenin was seen to have a detrimental effect on GFAP-IL6 mice 
who made more errors than apigenin fed WT mice. Yet, in all other test measures, either no 
effects, or only a genotype effect was observed. Similar to other measures, this disparity 
between the sexes may be a result of the low number of female mice in this study, or due to 
the possibility that apigenin affects males and females to a different extent. 
Assessment of recall memory was tested in the probe trial after a 72-hour rest period post 
acquisition trials. This was assessed in two different manners; firstly, for each test parameter, 
an assessment of any genotype and/or diet effect was conducted, and secondly, to provide an 
overall pattern of learning in the mice, the time spent in each quadrant in the Barnes maze 
was totalled for each genotype. For the latter analysis, it was necessary to group male and 
female mice together as the degrees of freedom was too low in female mice for analysis to 
occur. 
For most test parameters, for both males and females, no diet or genotype difference was 
observed. However, in both sexes, GFAP-IL6 mice made significantly less errors than WT 
mice. Most individual test measures in the probe trial, whilst providing insight into genotype 
differences for each particular parameter, may not completely represent changes in memory. 
Some parameters may demonstrate compounding non-cognitive factors such as anxiety, 
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exploration and level of mobility (187).  For example, primary path length may also show 
motor deficits in terms of gait. Secondly, as mentioned previously, mice tend to lose 
motivation over the testing period, so parameters such as total errors may not signify mistakes 
per se, but rather increased exploration, particularly since the escape hole was removed in the 
probe trial. 
To counter these compounding factors, we also considered the total time (out of a 90 second 
trial) the mice spent in each test quadrant (Q3 contains the escape hole), in addition to the 
total number of head entries in the replaced escape hole to ascertain how ‘insistent’ the mice 
were of the previous location of the escape hole.  
For the total number of head entries in the escape hole, where control fed GFAP-IL6 mice 
had performed worse the WT mice, the application of an apigenin-enriched diet resulted in 
GFAP-IL6 mice performing the same as WT mice. This suggests that apigenin was able to 
improve memory in male GFAP-IL6 mice to the same levels as those seen in male WT mice. 
In contrast, for females, no significant difference of diet and/or genotype in the number of 
head entries into the escape hole was observed. 
Apigenin did not appear to have an effect on the total time spent in each quadrant for either 
GFAP-IL6 or WT mice. However, it was found that genotype differences did exist. GFAP-
IL6 mice spent significantly more time in the escape hole quadrant (Q3), than the opposite 
quadrant (Q1). However, there was no difference in time spent between any other quadrants. 
In contrast, WT mice spent significantly longer in the escape hole quadrant (Q3), in 
comparison to the other three quadrants. This indicates that memory recall was inferior in 
GFAP-IL6 mice compared with WT mice, and that apigenin was not able to improve memory 
in GFAP-IL6 mice to the same levels seen in WT mice. This does suggest, however, that out 
model is valid to compare memory differences between GFAP-IL6 and WT mice. It is quite 
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possible that like other behavioural analyses in this study, that had we had enough data to 
analyse males and females separately, we may have observed different trends.  
To the knowledge of this author, no data testing the effects of apigenin on improving cognitive 
impairment with the use of the Barnes maze has been published. In other studies, apigenin 
has been seen to improve memory and learning in both young and aged animals in a number 
of MWM studies (188-190). A number of reasons may explain the discrepancy between the 
current study and published MWM studies. Firstly, in our experimental design, we clearly 
distinguish between learning (acquisition trials), and memory (probe), where we ascertain 
whether performance in a test parameter improved over the acquisition trials, and whether 
after a 72-hour rest period, the mice were able to remember the location of the escape hole. 
Conversely, no such distinction is made in the MWM, where testing is continuous, thus the 
lines between learning and memory are somewhat blurred. This means that any assessment 
of learning and memory is grouped together. That said, a rest period of 72 hours may be too 
long for mice to remember effectively. Probe trials are normally conducted after a 24-hour 
rest period (191), as demonstrated in a number of other studies where the probe trial was 
completed the day after the end of the acquisition trials (192, 193). This is likely to have had 
an effect on the memory outcomes in this study. 
Secondly, these studies have tested male animals only – no published study exists that 
separates male and female data for behavioural testing of apigenin. As shown in the current 
study, stronger effects are observed in male mice than in female mice, indicating that either 
we have not tested enough female mice, or that apigenin effects on memory and learning may 
be sex specific. Further investigation will be required to understand this trend. 
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Lastly, in comparison to the Barnes maze, MWM is highly stressful to the animals and thus 
more motivating (186). Therefore, the difference in stress levels induced between the two 
tests is likely to affect memory and learning outcomes.  
Compared with other phenotypes, learning and memory are difficult to assess (191), 
especially since cognitive abilities differ considerably between different mouse strains (192-
196). While, our model is validated in assessing motor function, further testing should focus 
on determining if memory and learning in our mouse model can be effectively validated with 
the use of the Barnes maze. Future experiments would benefit from adjusting certain 
experimental parameters such as low sample size and length of the rest-period between 
acquisition and probe trials as a beginning point in this assessment. 
 
6.2.4 Comparison of current study results with previous testing (at 8 months old) 
 
As mentioned previously, the mice used for experiments in this study had been previously 
involved in a number of behavioural tests at 8 months of age by another member of our 
laboratory (197). While there are considerable differences between the two studies with 
regards to the behavioural tests undertaken, test set-up, test parameters measured and 
analyses, some comparisons are able to be made. 
For instance, the current study demonstrated that apigenin fed WT male mice weighed 
significantly more than control fed WT male mice. During the initial phases of testing i.e. the 
first two months, weight changes and food consumption were monitored to assess the 
palatability of the new feed. These results showed that apigenin fed WT males weighed 
consumed significantly more feed than control fed WT males, and gained significantly more 
weight during that period. While we can only speculate as to whether this rate of higher 
 108 
 
consumption continued over the lifetime of the mice, leading to the higher weights observed 
in the present study, these earlier trends may explain the weight differences observed in this 
study. Future investigation should explore this trend further. 
In addition, the mice were tested in BM for both sets of experiments. Interestingly, at 8 months 
old, GFAP-IL6 male mice fed with apigenin had a significantly lower primary path length 
during the acquisition trials, than the WT male mice fed with apigenin.  In contrast, the current 
study demonstrated no significant difference in primary path length between the 
aforementioned groups during the acquisition trials. In neither study was this trend observed 
in female mice. These results may suggest a shift in the primary path length performance of 
male GFAP-IL6 mice in comparison to male WT mice over the course of the lifespan of the 
mouse. 
During the probe trial, at 8 months old, GFAP-IL6 mice demonstrated a significantly lower 
number of head entries to the escape hole than WT mice. Additionally, apigenin fed mice had 
a significantly higher number of head entries into the escape hole than control fed mice. This 
suggests the expected deterioration in memory in GFAP-IL6 mice, and also the expected 
recovery effects of apigenin. However, in contrast to the current study, no interactions were 
observed. In the current study, control fed GFAP-IL6 mice had a significantly lower number 
of head entries into the escape hole during the probe trial than control fed WT mice. However, 
in GFAP-IL6 and WT mice who were fed an apigenin diet, there was no significant difference, 
indicating that apigenin was able to improve memory of the location of the escape hole to 
those seen in WT mice.  
The reasons for any similarities or differences between the earlier experiments and the current 
study may be explained by numerous factors such as differences in analyses, experimental set 
up, and the number of mice available for experiments. Thus, direct comparisons are difficult, 
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and further research should be undertaken to compare the two sets of experiments more 
thoroughly.  
 
6.2.5 Future direction 
This research project contributes to the limited pre-clinical testing of apigenin in a mouse 
model of neuroinflammation, however further research can be directed to various other areas. 
Firstly, future experiments may benefit from adjusting certain parts of the current 
experimental set-up to address some of the limitations present in this study. For example, 
testing larger sample sizes, particularly for female mice, will provide a stronger basis for any 
conclusions drawn, and can give an indication of whether apigenin effects on motor and 
cognitive skills are, in fact, sex dependent. Additionally, apigenin effects on memory may be 
seen if the resting period is decreased between acquisition and probe trials in the Barnes maze. 
Behavioural studies should also be coupled with histology and apigenin concentrations in 
animal tissue to provide a more holistic model in understanding the effects of apigenin in 
treating neuroinflammation, and thus, neurodegenerative diseases. 
Successful pre-clinical studies may then justify the commencement of clinical trials to 
ascertain whether success seen in animal studies are translated into human patients.   
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7. Conclusion 
In the curcuminoid project, the aim was to determine the curcumin concentration in mouse 
chow pellets, which were fed to the mice used in this study, as well as to develop a valid LC-
MS/MS method to measure curcuminoid content in the plasma of mice fed either Meriva®, 
or naïve curcumin in a long-term feeding study. 
The results demonstrated that the mouse chow pellets contained approximately the correct 
concentrations, in terms of the concentrations expected. We concluded, therefore, that the 
mice were able to consume the experimental doses of curcumin for this study. 
Additionally, we found that the LC-MS/MS method developed was able to detect curcumin 
and demethoxycurcumin in low concentrations (ng/mL) in mouse plasma (free, conjugated or 
both), however, was not able to detect bisdemethoxycurcumin. A number of limitations were 
identified in the method, which may have affected our results, including substantial matrix 
effects and sensitivity issues. To address these limitations, several suggestions have been 
outlined. For instance, additional sample preparation techniques e.g. SPE, the addition of SIL 
analogue of the target analyte as an IS, and larger volume injections are all strategies which 
may help to improve the outcome of future studies. 
In determining plasma concentrations of curcuminoids, it was observed that free curcumin 
could be detected in plasma, only in the 140 mg/kg.bw/day naïve curcumin group. However, 
both 70 and 140 mg/kg.bw/day Meriva® groups had higher conjugate concentrations in 
plasma than the 140 mg/kg.bw/day naïve curcumin group, indicating that bioavailability for 
both these groups may have been initially higher than in the 140 mg/kg.bw/day naïve 
curcumin group, but that rapid liver metabolism resulted in higher levels of conjugates. We 
suggest that further study should focus on the bioactivity of curcuminoid conjugates, and the 
activity of both curcuminoids and conjugates in the peripheral immune response. 
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In the apigenin project, we tested the efficacy of apigenin in being able to improve motor 
function, memory and learning in a mouse model of neuroinflamamtion. Ours is the first study 
which investigates the role of apigenin in weight control. The results indicated that apigenin 
was able to promote weight gain/reduce weight loss in WT, but GFAP-IL6 mice, which may 
have implications in reducing age-related weight decline (due to muscle and skeletal mass 
loss), potentially reducing the risk of injury in the elderly population.  
Apigenin did not appear to improve motor function in our mouse model, however, a genotype 
effect was seen in a number of test parameters, validating our model. It was found that our 
results had differed from another study investigating the effects of apigenin in improving 
motor skills. This discrepancy may be due to the age of the mice used in this study, meaning 
that with increased age and thus, greater progression of neurodegenerative symptoms, the 
disease may eventually outweigh the benefits of the drug. 
Similarly, apigenin did not appear to improve overall learning, however, for many test 
parameters, a large effect size was seen, which suggests that with a greater sample size, we 
may have been able to see an improvement in learning over the acquisition trials. It was 
observed, however, that apigenin was able to improve performance in certain test parameters 
in male GFAP-IL6 mice compared to WT mice.  
Apigenin was able to improve memory within certain test parameters in male mice only. 
However, when male and female data was grouped to assess overall improvement in memory 
in total quadrant time, there was no significant improvement in memory. This may have been 
due to pooling male and female data, or perhaps apigenin affects can only be seen in individual 
test parameters. 
In summary, we find that apigenin was unable to improve motor function and learning, 
however, was able to be improve memory in male mice in certain test parameters. Whilst this 
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may be due to factors such as age of the mice/progression of neurodegenerative symptoms or 
low sample size, further research will be needed to ascertain the effect, if any, of these factors 
on any conclusions made in this study. In many test parameters assessing motor skills, a 
genotype effect was seen, which determines that our model is valid. However, this trend was 
not observed in Barnes maze test parameters, indicating that Barnes maze testing may be 
inappropriate for this model. Further studies should also be utilized to determine whether 
apigenin effects are sex-dependent. 
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8.  Appendices 
Appendix A (1-6). Curcuminoid calibration curves used to calculate 
curcuminoid concentration in Meriva® curcumin fed mouse plasma. 
UPLC/MS-MS analysis was conducted over day 1 and day 2, respectively, for 
curcumin (Appendix, A1-A2), demethoxycurcumin (Appendix, A3-A4), and 
bisdemethoxycurcumin (Appendix A5-A6). 10µL of plasma from a wild-type, 
control fed mouse was added to each sample to account for the matrix effect. 
NB: Errors exist for all data points, however, some are not reflected in the figures 
due to their minuteness.  
 
Appendix A1. Standard curve for curcumin in 1:1 ultrapure water: acetonitrile during 
day 1 of testing.  
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Equation Y = 227.1*X - 47.25
 
 
R square 0.9988 
Equation Y = 227.2*X – 20.26 
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Appendix A2. Standard curve for curcumin in 1:1 ultrapure water: acetonitrile during 
day 2 of testing.  
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Appendix A3. Standard curve for demethoxycurcumin in 1:1 ultrapure water: 
acetonitrile during day 1 of testing.  
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R square 0.9954 
Equation Y = 325.7*X – 204.1 
R square 0.9997 
Equation Y = 325.9*X – 25.53 
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Appendix A4. Standard curve for demethoxycurcumin in 1:1 ultrapure water: 
acetonitrile during day 2 of testing.  
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Appendix A5. Standard curve for bisdemethoxycurcumin in 1:1 ultrapure water: 
acetonitrile during day 1 of testing.  
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Appendix A6. Standard curve for bisdemethoxycurcumin in 1:1 ultrapure water: 
acetonitrile during day 2 of testing.  
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    R square 0.999
Equation Y = 609.8*X - 129.1
R square 0.9990 
Equation Y = 609.8*X – 129.1 
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Appendix B. Raw data tables showing UPLC/MS-MS AUC measurements 
for curcuminoids in mouse plasma. Raw data is shown for curcumin 
(Appendix B1), demethoxycurcumin (Appendix B2) and 
bisdemethoxycurcumin (Appendix B3). Nine representative samples were 
analysed for each sample (Reps 1-9), where three samples were prepared and 
measured in triplicate. Sample names followed by “U” represent untreated 
samples, and those followed by “T” represent samples treated with β-
Glucuronidase enzyme. 
 
Appendix B1. Raw AUC data for curcumin in mouse plasma, as measured by UPLC-
MS/MS 
 
Samples Rep 
1 
Rep 
2 
Rep 
3 
Rep 
4 
Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.00 0.00 0.00 0.00 0.00 0.00 25.83 0.00 0.00 
WT T 0.00 0.00 0.00 0.00 0.00 0.00 55.43 57.54 57.48 
GFAP-IL6 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-IL6 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 (NC) U 45.07 76.23 189.06 121.59 118.97 24.76 730.55 454.79 558.94 
140 (NC) T 4611.72 3651.42 3995.50 3150.24 3348.32 3077.57 2080.26 2326.96 2128.24 
35 U 16.61 0.00 0.00 0.00 0.00 0.00 15.89 39.57 27.41 
35 T 975.26 1433.26 1225.35 1511.61 1498.96 1498.30 926.76 870.35 788.06 
70 U 0.00 14.30 18.97 28.85 0.00 0.00 73.43 62.20 44.77 
70 T 3122.54 2802.46 3082.40 2173.28 2419.98 2150.23 1851.81 1643.22 2003.57 
140 U  39.41 11.08 36.66 27.42 4.99 64.04 56.81 16.90 68.86 
140 T (1:2) 2517.00 2848.53 3068.05 2398.56 2206.74 2508.83 2382.82 2674.81 3185.60 
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Appendix B2. Raw AUC data for demethoxycurcumin in mouse plasma, as measured 
by UPLC-MS/MS 
Samples Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.00 1.49 0.00 0.76 2.20 0.00 11.27 0.65 1.97 
WT T 1.29 2.49 13.58 7.83 15.13 3.62 3.65 8.76 11.55 
GFAP-IL6 U 0.14 0.54 0.04 0.66 0.93 0.20 1.85 1.53 1.12 
GFAP-IL6 T 7.94 29.53 1.48 7.27 9.93 17.21 16.94 15.74 18.59 
140 (NC) U 0.00 0.00 0.00 10.27 12.01 9.00 12.39 13.81 0.94 
140 (NC) T 117.94 155.62 240.24 101.44 172.49 260.48 138.87 211.37 60.23 
35 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.27 1.51 
35 T 53.77 64.14 38.97 44.36 32.57 36.41 27.87 39.52 44.48 
70 U 0.00 0.00 0.00 0.00 0.00 0.00 3.10 0.92 0.81 
70 T 95.72 40.34 82.43 70.23 23.96 25.70 114.56 36.32 35.25 
140 U  0.00 0.00 0.00 0.00 0.00 0.00 1.98 28.97 10.97 
140 T (1:2) 90.53 20.09 104.80 24.64 68.09 118.24 38.59 104.48 50.35 
 
 
 
Appendix B3. Raw AUC data for bisdemethoxycurcumin in mouse plasma, as 
measured by UPLC-MS/MS  
Samples Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
WT T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-IL6 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-IL6 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 (NC) U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 (NC) T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
35 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
35 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
70 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
70 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 U  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 T (1:2) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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Appendix C. Calculated curcuminoinoid concentrations measured in mouse 
plasma. Curcuminoid concentrations are displayed for curcumin (Appendix C1), 
demethoxycurcumin (Appendix C2) and bisdemethoxycurcumin (Appendix 
C3). Cells highlighted in yellow indicate concentrations calculated from 
standard curves created on day 1 of testing, whereas cells highlighted in blue 
indicated concentrations calculated from standard curves created on day 2 of 
testing (as seen in Appendix 1). Nine representative samples were analysed for 
each sample (Reps 1-9). ), where three samples were prepared and measured in 
triplicate. Sample names followed by “U” represent untreated samples, and 
those followed by “T” represent samples treated with β-Glucuronidase enzyme. 
 
Appendix C1. Calculated curcumin concentration in mouse plasma, after feeding with 
Meriva® curcumin for one month. Concentrations were calculated from straight line 
equations derived from the generation of standard curves, produced on day 1 of testing (cells 
highlighted in yellow) and day 2 (cells highlighted in blue). 
 
Sample Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.000 0.000 0.000 0.000 0.000 0.000 0.706 0.000 0.000 
WT T 0.000 0.000 0.000 0.000 0.000 0.000 0.797 0.803 0.803 
GFAP-IL6 U 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
GFAP-IL6 T 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
140 (NC) U 0.288 0.425 0.921 0.624 0.613 0.198 2.870 2.023 2.343 
140 (NC) T 14.786 11.838 12.894 10.299 10.907 10.076 7.014 7.771 7.161 
35 U 0.162 0.000 0.000 0.000 0.000 0.000 0.675 0.748 0.711 
35 T 4.382 6.398 5.482 6.742 6.687 6.684 3.472 3.299 3.046 
70 U 0.000 0.152 0.173 0.216 0.000 0.000 0.852 0.818 0.764 
70 T 13.833 12.424 13.656 9.655 10.740 9.553 6.312 5.672 6.778 
140 U  0.263 0.138 0.251 0.210 0.111 0.371 0.801 0.679 0.838 
140 T (1:2) 8.355 9.373 10.047 7.991 7.402 8.330 7.943 8.839 10.407 
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Appendix C2. Calculated demethoxycurcumin concentration in mouse plasma, after 
feeding with Meriva® curcumin for one month. Concentrations were calculated from 
straight line equations derived from the generation of standard curves, produced on day 1 of 
testing (cells highlighted in yellow) and day 2 (cells highlighted in blue).  
 
Sample Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.000 0.000 0.000 0.000 0.000 0.000 0.706 0.000 0.000 
WT T 0.000 0.000 0.000 0.000 0.000 0.000 0.797 0.803 0.803 
GFAP-IL6 U 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
GFAP-IL6 T 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
140 (NC) U 0.288 0.425 0.921 0.624 0.613 0.198 2.870 2.023 2.343 
140 (NC) T 14.786 11.838 12.894 10.299 10.907 10.076 7.014 7.771 7.161 
35 U 0.162 0.000 0.000 0.000 0.000 0.000 0.675 0.748 0.711 
35 T 4.382 6.398 5.482 6.742 6.687 6.684 3.472 3.299 3.046 
70 U 0.000 0.152 0.173 0.216 0.000 0.000 0.852 0.818 0.764 
70 T 13.833 12.424 13.656 9.655 10.740 9.553 6.312 5.672 6.778 
140 U  0.263 0.138 0.251 0.210 0.111 0.371 0.801 0.679 0.838 
140 T (1:2) 8.355 9.373 10.047 7.991 7.402 8.330 7.943 8.839 10.407 
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Appendix C3. Calculated bisdemethoxycurcumin concentration in mouse plasma, after 
feeding with Meriva® curcumin for one month. Concentrations were calculated from 
straight line equations derived from the generation of standard curves, produced on day 1 of 
testing (cells highlighted in yellow) and day 2 (cells highlighted in blue). 
 
Samples Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
WT T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-
IL6 U 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-
IL6 T 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 
(NC) U 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 
(NC) T 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
35 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
35 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
70 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
70 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 U  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 T 
(1:2) 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
Samples Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Rep 6 Rep 7 Rep 8 Rep 9 
WT U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
WT T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-IL6 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
GFAP-IL6 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 (NC) U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 (NC) T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
35 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
35 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
70 U 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
70 T 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 U  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
140 T (1:2) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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Appendix D (1-4). Mouse behaviour experimental protocols used in the 
apigenin project. Behavioural protocols are shown for physical battery testing 
(functional motor activity; Appendix D1), walking beam (Appendix D2), 
accelerod (Appendix D3), and Barnes maze (Appendix D4). 
 
Appendix D1. Protocol for Functional motor activity as assessed as part of physical 
battery assessment of mice prior to behavioural testing. Each mouse was allocated a 
score for each section (A-D), which was summed to create an overall score for functional 
motor activity. 
 
Functional motor activity 
A. Gait Observation Score: 
The animal is removed from its cage and placed on a flat surface with its head 
facing away from the investigator. The mouse is observed from behind as it 
walks. The mouse is placed back into its cage and a gait score is recorded from 
the following:  
 
0 = If the mouse moves normally, with its body weight supported on all limbs, 
with its abdomen not touching the ground, and with both hindlimbs 
participating evenly. 
1= If it shows a tremor or appears to limp while walking. 
2 = If it shows a severe tremor, severe limp, lowered pelvis, or the feet point 
away from the body during locomotion (“duck feet”) 
3 = If the mouse has difficulty moving forward and drags its abdomen along 
the  ground.  
 
 
 123 
 
 
B. Kyphosis Observation Score: 
The mouse is removed from its cage and placed on a flat surface. The animal 
is observed as it walks. After observation the mouse is placed back in its cage 
and a kyphosis score is assigned from the following: 
 
0 = Able to easily straighten its spine as it walks, and does not have persistent 
kyphosis. 
1 = If the mouse exhibits mild kyphosis but is able to straighten its spine. 
2 = If it is unable to straighten its spine completely and maintains persistent 
but mild kyphosis. 
3 = If the mouse maintains pronounced kyphosis as it walks or while it sits.  
 
C. Ledge Test 
Lift the mouse from the cage and place it on the cage's ledge. The tendency 
will be for the animals to walk along the ledge and then attempt to descend 
back into the cage. Observe the mouse walk on the ledge and lower itself into 
the cage. Assign a score: 
0 = (Normal) If the mouse walks along the ledge without losing its balance, 
and lowers itself back into the cage gracefully, using its paws. 
1 = If the mouse loses its footing while walking along the ledge, but otherwise 
appears coordinated. 
2 = If it does not effectively use its hind legs, or lands on its head rather than 
its paws when descending into the cage. 
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3 = If it falls off the ledge, or nearly so, while walking or attempting to lower 
itself, or shakes and refuses to move at all despite encouragement. 
 
D. Hindlimb clasping 
Grasp the tail near its base and lift the mouse clear of all surrounding objects. 
Observe the hindlimb position for 10 seconds. Place the mouse back into its 
cage and record its hindlimb clasping score from the following: 
 
0 = If the hindlimbs are consistently splayed outward, away from abdomen 
1 = If one hindlimb is retracted toward the abdomen for more than 50% of the 
time suspended. 
2 = If both hindlimbs are partially retracted toward the abdomen for more than 
50% of the time suspended. 
3 = If its hindlimbs are entirely retracted and touching the abdomen for more 
than 50% of the time suspended. 
 
Appendix D2. Walking Beam Test: Protocol  
 
Objective: 
The walking beam is designed to assess balance and motor coordination of rodents. Mice are 
trained to traverse several elevated narrow beams to reach a goal box located on the end 
platform. Parameters measured include latency to cross the narrow beam, whether the animals 
fall from the beam, and the number of hindpaw or forepaw footslips that occur while the 
mouse crosses. 
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Scope and applicability: 
The walking beam offers improved sensitivity in determining fine motor coordination and 
balance impairments in mouse models of neurodegenerative disorders, or to evaluate the 
effects of therapeutic interventions. This test is also commonly used to test sensorimotor 
function in cortical lesion, stroke and aging rodent models. 
Materials/apparatus: 
 Walking beams are usually constructed in-house, made of wood and around a metre 
in length, with a beam width of less than 5cm. Test sensitivity is increased by the use 
of various beams of different shapes and widths.  
 
 The apparatus constructed in our laboratory utilises a good compromise as suggested 
by Brooks 2001, with the use of a tapered beam that narrows as the mouse traverses 
toward the goal box. The widest width of the beam at the start end measures 1.5cm, 
narrowing along the length to 0.5cm at the end point. There is a ledge running on 
either side of the beam of approx. 1 cm from the top, and 1cm wide, to allow the visual 
assessment of foot slips. There are defined stop and start points on the beam marked 
by dots to time the mice traversal, in order to reduce variance of the data. There is a 
goal box located at the end point to encourage mice to traverse the beam, with two 60-
watt desk lamps placed on either side of the beam on the starting end, to further direct 
mice to cross the beam. The support stands measure 50cm in height, with soft bedding 
material placed under the apparatus to ensure mice are not hurt if they fall. The beam 
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can also be inclined toward the goal box to encourage mice to move along the beam, 
utilising the natural tendency of mice to run upwards to escape. Bedding from the 
home cage can also be introduced into the goal box to further motivate the mice to 
traverse the beam.   
 
 A video camera is attached to a tripod and positioned on the goal box side of the beam 
to be able to capture and assess the foot slips post hoc during the testing trials.  
 
 Supplies of 50% ethanol and paper wipes. 
 
Procedure: 
Training: 2 Days 
1. Mice are transported on a trolley in their home cages from the animal facility to the 
behavioural lab and placed in the designated holding area in the lab. Mice are left to 
habituate to the experimental room for 30 min.  
 
2. Conditions in the experimental room are kept constant (temperature, light intensity, 
humidity), and excess noise, human activity and distractions kept to a minimum.  
 
3. A record sheet with all test animal IDs, cage number, and ear markings is kept with 
the order of the animal trials pre-determined for time efficiency.   
 
4. Following the habituation period, all animals are identified by matching their ear 
marks with their animal ID, and assigned tail markings with a non-toxic permanent 
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marker. Corresponding tail markings with animal ID numbers are recorded on the 
record sheet. 
 
5. To prevent influences on performance, all cages with male mice are tested first, 
followed by all female mice cages. 
 
6. Following the habituation period, the two desk lamps are turned on so they illuminate 
the start zone of the beam.  
 
7. A mouse is picked up by the base of the tail and placed at the start of the beam at the 
widest part. The mouse is allowed to briefly sniff the area, and is assisted to cross the 
beam toward the goal box by orienting the mouse with the hand and gently nudging 
the animal to encourage movement along the beam.  
 
8. If the mouse stops to sniff midway or falls off the beam, the mouse is corrected to 
keep moving or picked up and placed in the same spot where it fell off. 
 
9. The time taken to traverse the beam is recorded with a stopwatch (max 60 sec). The 
mouse is given 3 consecutive trials, alternating between mice so that each mouse has 
an inter-trial-interval of at least 30 seconds, then returned to its home cage. Counting 
starts when the mouse makes its first step forward from the start line, and ends when 
all four limbs have crossed the finish line.  
 
10. Between mice the apparatus is cleaned with 50% ethanol and allowed to evaporate 
before placing the next mouse on the apparatus.  
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11. These steps are repeated for all additional mice. 
 
12. To obtain a stable baseline, repeat training over 2 consecutive days, providing assisted 
trials on Day 1 and unassisted trials on Day 2. 
  
Testing: 1 Day 
13. Apparatus and procedures are kept the same as in training sessions (Steps 1-11), with 
the exception that the video camera is set up to record all trials, with the angle view 
from behind the mouse along the length of the beam. 
 
14. Cards are labelled with each mouse’s ID numbers and placed in front of the camera to 
identify which mouse is being trialled.  
 
15. Mice are given 3 consecutive trials on the test day, the first run serves as a refresher, 
with the remaining two trials for data collection (total of 120s for the two trials).   
 
16. If an animal falls from the beam on two consecutive trials, it is scored the maximum 
traverse time allowed of 120s and may be removed from the study. 
 
17. Animals that do not cross within the 60 s trial are allocated the maximum value of 60s 
for analysis. 
 
 
 129 
 
Analysis of Video 
Forepaw slips are rare, so they are not analysed. The number of hindpaw (left and right) slips 
are scored by the examiner from the video viewed in slow motion, preferably blind to 
genotype. When the limb slips 0.5cm below the beam surface it is considered a footslip. Slips 
are counted only when the mouse is moving forward, while slips made after stopping or 
moving its head are not counted. On the narrow end of the beam, if the base of the hindpaws 
are on the beam and the toes are hanging off the side, this is not considered a footslip. The 
number of falls are also recorded.  
 
Protocol adapted from the following sources: 
Brooks SP, Pask T, Jones L, Dunnet SB (2004) Behavioural profiles of inbred mouse strains 
used as transgenic backgrounds. I: motor tests. Genes, Brain and Behavior 3: 206-215 
Carter RJ et al. (1999) Characterization of progressive motor deficits in mice transgenic for 
the human Huntington's disease mutation. J Neurosci 19:3248-3257 
Carter RJ, Morton AJ, Dunnet SB (2001) Motor coordination and balance in rodents. Current 
Protocols in Neuroscience, unit 8.12.1-14. John Wiley & Sons, Inc. 
Crawley JN (1999) Behavioural phenotyping of transgenic and knockout mice: experimental 
design and evaluation of general health, sensory functions, motor abilities, and specific 
behavioural tests. Brain Res 835:18-26 
Crawley JN. (2007) What’s wrong with my mouse? Behavioral phenotyping of transgenic 
and knockout mice. New York: John Wiley and Sons, Inc.  
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Fleming SM, Ekhator OR, and Ghisays V. (2013) Assessment of Sensorimotor Function in 
Mouse Models of Parkinson's Disease. J Vis Exp. 2013; (76): 50303.Published online Jun 17, 
2013. doi:  10.3791/50303 PMCID: PMC3727502 
Stanley JL, Lincoln RJ, Brown TA, McDonald LM, Dawson GR, Reynolds DS (2005). T he 
mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining 
motor coordination deficits induced by benzodiazepines. J Psychopharmacol, 19(3): p. 221-
7. 
 
Appendix D3. Accelerod: Protocol 
 
Purpose: 
The accelerod test is used to assess motor coordination and balance in rodents. Mice have to 
keep their balance on a rotating rod. It is measured the time (latency) it takes the mouse to 
fall off the rod rotating at different speeds or under continuous acceleration (e.g. from 4 to 
40rpm). 
 
Scope: 
 Individuals  who  have  been  trained,  and  are  competent  in  performing  the procedures 
described herein must follow this procedure strictly. 
 
Any queries, comments or suggestions, either relating to this SOP in general or to a specific 
problem encountered during a procedure, should be addressed to the Head of Phenotyping 
Facility. 
 
Any deviances from this protocol must be agreed by the Head of Phenotyping Facility. 
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Safety Requirements: 
General laboratory procedures should be followed, which include: no eating, no chewing 
gum, no drinking, and no applying of cosmetics in the work area. Laboratory coats and gloves 
must be worn at all times in the work area, unless the protocol specifically describes the 
appropriate attire for the procedure. 
 
Notes: 
 The validity of results obtained from behavioural phenotyping is largely dependent on 
methods of animal husbandry. It is of vital importance that individuals following this 
procedure are experienced and aware of the animal’s welfare, and is familiar with the 
animal being tested, in order to reduce the anxiety levels of the animal prior to testing. 
 
 The majority of mouse behavioural studies are age/sex/strain dependent.   It is 
important to keep track of them experiment. 
 
 Body weight might influence performance in this test. Thus, consideration of body 
weight is essential for better evaluation of the data. 
 
 Environmental factors may contribute to the levels of anxiety within the mouse. 
 
 The temperature, humidity, ventilation, noise intensity and lighting intensity must be 
maintained at levels appropriate for mice.   It is essential that the mice be kept in a 
uniform environment before and after testing to avoid anomalous results being 
obtained. 
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 There is no training period prior to the test phase. 
 
 It is recommended that all phenotyping experimentation is conducted at approximately 
the same time of day because physiological and biochemical parameters change 
throughout the day. 
 
 Check if there is space in the camera memory. Set up camera and record. 
 
Equipment: 
Commercially available accelerod apparatus as described below: 
Dimensions of the apparatus: Rotating rod diameter is ca. 9cm made of hard plastic 
material covered by grey rubber (cut from insulation material to cover water pipes); lanes 
width is ca. The apparatus must allow an accelerating speed from 4rpm to 40rpm in 300 sec. 
 
Supplies: 
EtOH 50% 
Paper towels 
 
Procedure: 
 On the day of testing, mice should be kept in their home cages and acclimate to the 
testing room for at least 30 min (acclimation phase). 
 
 For ease of identification at later trials, mark the mice, using non-toxic ink, with 
respective stripes at the base of the tail before testing. 
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 Clean the apparatus with Alcohol 70 % after each trial. 
 
 Turn on the accelerod apparatus. 
 
Test phase 
 It consists of three trials separated by 30-45 min inter-trial intervals (ITI). It is possible 
to run the next batch of mice consecutively in one trial before moving to the next. There 
is no training period prior to the test phase. 
 
 Set apparatus to accelerating mode from 4 to 40rpm in 300sec. The apparatus will 
indicate “acceleration waiting” of 4rpm constant speed until the start button is pressed. 
 
 Test trial 1 (T1): place the mice on the lanes (if handling the mice is difficult leave 
an empty lane between two mice and measure only 3 mice per run). 
 
 Try to have the mice on the rod walking forward to keep their balance. The rod is 
initially rotating at 4rpm constant speed to allow positioning of all the mice in their 
respective lanes. Once all the mice are “ready” (i.e. check that they are able to walk 
forward for a few seconds at 4 rpm) push the start button and the rod will be accelerating 
from 4 rpm to 40 rpm in 300 sec. 
 
o Record the latency at which each mouse falls off the rod. 
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 Remove the mouse and place it back in its home cage. Be very careful not to disturb 
the other mice that are still running in the adjacent lanes. Also make a note of passive 
rotation on the data sheet. 
 
 Clean apparatus with water then with 70% EtOH, wipe it dry.  Test the next set of mice 
repeating the procedure for trial 1 as in 9.4.2- 9.4.4. 
 
 Leave a 30-45 min inter trial interval (ITI) between consecutive trials of the same 
batch of mice (e.g. T1-ITI-T2-ITI-T3). 
 
 At the end of trial 3, weigh each mouse and make a note of the body weight on the 
data sheet. 
 
 Note on the data sheet any observations during the test, including occurrence of 
jumping, passive rotations time etc. 
 
 The whole test for three sets of mice, excluding the acclimation phases (at least 15 
min), will require approx. 1h and, 45 min. 
 
Data recorded 
 Latency to fall -t1 
 Passive rotation -t1 (yes/no)  
 Latency to fall -t2 
 Passive rotation -t2 (yes/no)  
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 Latency to fall -t3 
 Passive rotation -t3 (yes/no)  
 Latency to fall -mean 
 Body weight 
 Comments 
 
Supporting information: 
Brooks SP, Pask T, Jones L, Dunnet SB (2004) Behavioural profiles of inbred mouse 
strains used as transgenic backgrounds. I: motor tests. Genes, Brain and Behavior 3: 206-
215 
 
 Carter RJ et al. (1999) Characterization of progressive motor deficits in mice transgenic for 
the human Huntington's disease mutation. J Neurosci 19:3248-3257 
 
 Carter RJ, Morton AJ, Dunnet SB (2001) Motor coordination and balance in rodents. 
Current Protocols in Neuroscience, unit 8.12.1-14. John Wiley & Sons, Inc. 
 
 Caston J, Jones N, Stelz T (1995) Role of preoperative and postoperative sensorimotor 
training on restoration of the equilibrium behaviour in adult mice following 
cerebellectomy. Neurobiol Learn Mem 64:195-202 
 
           Caston J, Vasseur F, Stelz T, Chianale C, Delhaye-Bouchaud N, Mariani J (1995) 
Differential roles of cerebellar cortex and deep cerebellar nuclei in the learning of the 
equilibrium behaviour: studies in intact and cerebellectomized Lurcher mice. Devel Brain 
Res 86:311-316 
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Crawley JN (1999) Behavioural phenotyping of transgenic and knockout mice: experimental 
design and evaluation of general health, sensory functions, motor abilities, and specific 
behavioural tests. Brain Res 835:18-26 
 
 Dunham NW, Miya TS (1957) A note on a simple apparatus for detecting neurological 
deficit in rats and mice. J Am Pharmac Assoc Sci Ed 46:208-209 
 
 Hilber P, Caston J (2001) Motor skills and motor learning in Lurcher mutant mice during 
aging.  Neuroscience 102:615-623 
 
 McFadyen MP, Kusek G, Bolivar VJ, Flaherty L (2003) Differences among eight inbred 
strains of mice in motor ability and motor learning on a rotorod. Genes, Brain and Behavior 
2: 214-219 
 
  Rozas G, Guerra MJ, Labandeira-Garcia JL (1997). An automated rotarod method for 
quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. 
Brain Res Prot 2:75-84 
 
  Rustay NR, Whalsten D, Crabbe JC (2003) Assessment of genetic susceptibility to ethanol 
intoxication in mice. Proc. Natl. Acad. Sci. USA 100: 2917-2922. 
 
History review 
In this version, only the latency is recorded. Passive rotations are recorded for each trial 
for potential subsequent analysis. 
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In the previous versions: 
10_009, Version 1: the speed of rotation was also recorded and the foam rubber cover was 
standardized. 
10_009, Version 0: there was no homogeneous foam rubber cover between all partners. 
Pre-training and 4 testing trials were performed. 
 
Appendix D4. Barnes Maze: Protocol 
 
Objective 
The Barnes Maze (BM) is a type of navigational maze used to assess spatial learning and 
memory in rodents. The maze consists of an elevated circular platform with evenly spaces 
holes around the perimeter. Animals are given reinforcement and visual clues to escape from 
the exposed, brightly lit platform to a dark recessed target hole. Improvement in their ability 
over trials is thought to signify the animal’s learning and memory of the escape target hole. 
The maze uses the rodents’ instinct to seek out dark, enclosed spaces and avoid open, bright 
spaces. It has been used to test both reference and working memory the protocol described 
here is a shortened protocol adapted from the methods by Sunyer et al 2007 and Attar et al 
2013. 
 
Scope and applicability 
The BM was invented by Carol Barnes in 1979 as an alternative to the stress caused by the 
Morris Water Maze (MWM), initially developed for rates, However the BM has now been 
adapted to, and more frequently used in mice, as it utlilises the natural tendencies and abilities 
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of mice to search and escape through small holes the maze’s capacity to measure spatial ability 
has been confirmed by rodents with hippocampal damage showing impaired performance. 
Although similar to MWM and radial-arm maze task, this maze does not require strong 
aversive stimuli or food deprivation as motivation 
 
Safety requirements: 
Individuals must be trained and competent with the procedures, equipment and handling of 
animals described in this protocol. 
General PC2 laboratory safety procedures must be followed 
 
Materials/Apparatus: 
The maze: 
The BM (Fig 29) is made of a circular platform 91cm in diameter, with 20 equally spaced 
holes of 5cm diameter around the periphery, elevated 90cm above the floor. Only one of the 
holes is fitted with a small dark recessed chamber through which the mice can escape. The 
mouse cannot visually discriminate between the escape hole and the blocked holes from the 
maze surface. Soft padding material is laid down beneath the apparatus to prevent any injuries 
should the mice fall off during testing. 
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Fig 29. The Stoelting Barnes maze apparatus. 
 
Reinforcement: 
Our laboratory uses aversive noise of 85dB as a motivator, in addition to bright lighting 
(950 lux). The noise type is kept consistent throughout testing 
 
Room configuration and visual cues: 
Reference points for rodents to locate the target escape hole are provided. These include 4 
different shapes mounted around the maze as intra-maze visual cues, in addition to extra-
maze spatial cues from the furniture and equipment located around the room. These cues are 
kept exactly the same for each mouse during testing. 
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Video-tracking software: 
Digital camera and the ANY-maze tracking system is utilised to capture all data. An 
observer is always present to check for any tracking errors during the trials. 
Other: 
 Isolation box 
 Black starter chamber 
 Stopwatch 
 Paper towels 
 70% ethanol solution spray 
 Clean empty cages for animal transfer 
 Personal protective equipment (e.g. lab coat, gloves) 
 
Procedure: 
The BM test is typically performed as per the experimental sequence below. All work is 
conducted between 8.00am -2.00pm: 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
1 habituation 
trial 
3 acquisition 
trials 
3 acquisition 
trials 
Break Break 1 probe trial 
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Preparation: 
The following steps are followed in the morning of each experimental day: 
1. Animals are transported in their home cages from the animal facility to the behaviour 
laboratory, carried on one of the animal facility’s corridor trolleys, with a sheet covering the 
cages during the transport to the laboratory. 
2. Mice to be tested are placed in the low lighting isolation box (-10 lux) with the fan on to 
habituate in the setting for 30 minutes. 
3. Excess noise, human activity, odours and visual distractions are avoided 
4.  A record sheet with all test animal IDs, cage number, and ear markings is kept with the 
randomized order of the animal and escape hole locations pre-determined for efficiency. 
5. The maze, all benches, and all surfaces where animals are to be handles are wiped down 
with 70% ethanol spray. 
 
Day 1 – 1 habituation trial 
Testing order: As there is only one habituation trial performed for the day, all animals in a 
cohort can be run one after the other. 
1. Mice are carefully identified by matching their ear markings with the animal ID. With the 
laboratory lights dimmed (-30 lux), the mouse to be tested is carried over in a clean transfer 
cage to the experimental area. This aids to minimize the cross-over of odours between animals 
and sex. 
2. The mouse is then carefully places in the cylindrical black start chamber. The start chamber 
with the mouse is placed at the centre of the maze for 10s. After 10s have passed, the chamber 
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is lifted and the aversive stimuli is turned on (sound 85dB and all laboratory lights switched 
on at 950 lux). 
3. The mouse is gently guided to the escape hole. The mouse should not be forced to enter the 
escape hole. Instead, if it is resisting entering the hole, the animal is placed gently to the side 
of the hole and pulled gently by the base of the tail in the direction away from the hole, which 
should induce the mouse to move in the opposite direction to enter the hole. Should this 
manoeuvre not work, the mouse is placed directly in the hole. 
4. When the mouse is in the escape hole, all aversive stimuli is switched off. 
5. The mouse is kept in the escape hole for 2 minutes. Place a cover over the hole to prevent 
the mouse from escaping during the 2 minutes. 
6. After the 2 minutes have passed, the mouse is carefully taken out of the escape hole and 
placed back in its transfer cage. Great care must be taken when sliding the escape hole drawer 
out to ensure no part of the mouse gets trapped (tail and head are susceptible). The mouse is 
then returned to its home cage and placed in a designated holding area outside the lab so they 
are not exposed to the aversive noise. 
7. Between each trial, the apparatus and experimental surfaces are thoroughly cleaned with 
70% ethanol solution spray to remove any faeces or urine, and allowed time to dry. The 
experimenters’ gloves are also sprayed with 70% ethanol before picking up the next test 
animal. 
8. Recording and tracking of the habituation trial is optional. 
9. Once all testing is completed for the day, the animals are returned to the animal facility as 
per step 1, section 5.1. 
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Days 2 and 3 – 3 acquisition trials 
Testing order: Mice are tested in groups of up to 5 in order to maintain a similar inter-trial 
interval (ITI). Once the first group of mice complete their 3 acquisition trials for the day, then 
the next group of mice are run. 
1. The ANY-Maze program is prompted to commence recording and tracking of the animal’s 
movements in the maze for a fixed period of 3 minutes. Examples of parameters to records 
include: primary and total latency, primary and total path length, as well as primary and total 
errors. 
2. Mice are carefully identified by matching their ear markings with the animal ID. With the 
laboratory lights dimmed (-30 lux), the mouse to be tested is carried over in a clean transfer 
cage to the experimental area, carefully taken out and place at the centre of the maze for 10s. 
After 10s have passed, the chamber is lifted and the aversive stimuli is turned on (sound 85dB 
and all laboratory lights switched on at 950 lux), and the mouse is allowed to freely explore 
the maze for 3 minutes. The experimenter should quickly move completely out of view behind 
the black curtain. 
3. The trial ends when the mouse enters the escape hole or when 3 minutes have elapsed. 
4. If the mouse has successfully entered the escape hole before 3 minutes, the aversive stimuli 
is turned off and the mouse is made to stay in the escape hole for 1 minute, closing the entrance 
so it does not venture out. 
5. If the mouse does not enter the escape hole within 3 minutes, the experimenter gently guides 
the mouse to the escape hole and is left inside for 1 minute, turning aversive stimuli off once 
it is in the escape hole. 
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6. The mouse is placed back in its transfer cage and returned to its home cage in the isolation 
box. 
7. After each trial, the apparatus and experimental surfaces are thoroughly cleaned with 70% 
ethanol solution spray to remove any faeces or urine, and allowed time to dry. The 
experimenters’ gloves are also sprayed with 70% ethanol before picking up the next test 
animal. 
8. Steps 1-7 (Section 5.3) are repeated until each animal has completed 3 trials for the day. 
Animals will do a total of 6 acquisition trials over the 2 days. 
9. A 20-30 minute ITI is maintained for all animals. 
10. Once one group of animals have finished testing for the day, they are placed in a 
designated holding area just outside the lab so that they are not exposed to the aversive noise. 
11. When all groups have completed testing, they are returned to the animal facility as per 
step 1, section 5.1. 
 
Day 6 – 1 probe trial 
Testing order: All animals in a cohort can be run one after the other as there is only one probe 
trial. 
72 hours after day 2 of acquisition trials, the probe trial is conducted. The experiment is run 
exactly as the acquisition trials, except that the escape hole is replaced with a closed hole, the 
test duration is reduced to 90 seconds, and there is only 1 trial. 
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The probe trial is performed to determine whether the mouse can remember where the escape 
hole had previously been located. The number of nose pokes in holes other than the target 
hole (errors), latency and path length to reach the target hole are measured. 
 
Supporting sources of information: 
Attar A, Liu T, Chan WT, Hayes J, Nejad M, Lei K, Bitan G (2013). A shortened Barnes 
maze protocol reveals memory deficits at 4-months of age in the triple-transgenic mouse 
model of Alzheimer’s disease. PLos One. Nov 13; 8(11):e80355. 
Doi:10.1371/journal.pone.0080355 
Barnes, CA (1979). Memory deficits associated with senescence: a neurophysiological and 
behavioural study in the rat. J Comp Physiol Psychol. 93: 74-104 
Crawley JN (2007). What’s wrong with my mouse? Behavioural phenotyping of transgenic 
and knockout mice. New York: John Wiley and Sons, Inc. 
Dawood MY, Lumley LA, Robinson CL, Saviolakis GA, Meyerhoff JL (2004). Accelerated 
Barnes maze test in mice for assessment of stress effects on memory. Ann N Y Acad Sci. 
Dec; 1032:304-7 
Inman-Wood SL, Williams MT, Morford LL, Vorhees CV (2000). Effects of prenatal cocaine 
on Morris and Barnes maze tests of spatial learning and memory in the offspring of C57BL/6J 
mice. Neurotoxicol Teratol. Jul-Aug; 22(4):547-57 
O’Leary TP, Brown RE (2009). Visuo-spatial learning and memory deficits on the Barnes 
maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer’s disease. Behav 
Brain Res. Jul19; 201(1):120-7. Doi:10.1016/j.bbr.2009.01.039 
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O’Leary TP, Brown RE (2012). The effects of apparatus design and test procedure on learning 
and memory performance of C57BL/6J mice on the Barnes maze. J Neurosci Methods. Jan30; 
203(2):315-24. doi: 10.1016/j.jneumeth.2011.09.027 
O’Leary TP, Brown RE (2013). Optimization of apparatus design and behavioral measures 
for the assessment of visuo-spatial learning and memory of mice on the Barnes maze. Learn 
Mem. Jan15; 20(2):85-96. Doi:10.1101/lm.028076.112.63 
Patil SS, Sunyer B, Höger H, Lubec G (2009). Evaluation of spatial memory of C57BL/6J 
and CD1 mice in the Barnes maze, the Multiple T-maze and in the Morris water maze. Behav 
Brain Res. Mar2:198(1):58-68. doi: 10.1016/j.bbr.2008.10.029 
Rosenfeld, CS, Ferguson SA (2014). Barnes maze testing strategies with small and large 
rodent models. J. Vis. Exp. (84), e51194, doi: 10.3791/51194 
Sunyer B, Patil S, Höger H, Lubec G (2007). Barnes maze, a useful task to assess spatial 
reference memory in the mice. Protocol exchange doi: 10.3791/51194 
Urbach A, Robakiewicz I, Baum E, Kaczmarek L, Witte OW, Filipowski RK (2013). Cyclin 
D2 knockout mice with depleted adult neurogenesis learn Barnes maze task. Behav Neurosci. 
Feb127 (1):1-8. Doi: 10.1037/a003122 
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